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     ABSTRACT 
Background: The hallmark of HIV infection is immunosuppression which predisposes to 
unusual infections and malignancies generally known as opportunistic diseases (ODs). Globally, 
ODs are the major cause of morbidity and mortality in people living with HIV (PLHIV). Since 
the advent of Highly Active Antiretroviral Therapy (HAART), a significant decline in AIDS 
progression and ODs has been observed globally. However, most of the evidence suggesting 
sustained decline in AIDS progression and ODs has come from high-income settings with 
relatively less burden of ODs in the pre-HAART era. The findings of studies in high-income 
settings may not be generalizable to resource-limited settings. Lack of information regarding the 
burden of ODs in HAART-experienced populations in Nigeria and the risk factors for their 
occurrence has made it difficult to fully assess the sustained efficacy of HAART in the country. 
The aim of this study was to investigate the prevalence of and risk factors for HIV-related 
opportunistic diseases amongst HAART patients at the Federal Medical Centre (FMC) in 
Owerri, Nigeria. 
Study design and setting: A quantitative, cross-sectional descriptive and analytical study was 
conducted with 354 adult HIV-infected patients 15 years and above, who were on HAART for a 
minimum of 12 weeks at the HIV clinic of the FMC, Owerri, South-east Nigeria. Patients 
currently manifesting an OD whose onset ante-dated the commencement of HAART were 
excluded. The participants were recruited by simple random sampling. 
Data collection: Using a structured questionnaire, data was collected by clinicians through 
interviews, physical and laboratory examinations for patients that provided informed consent and 
met the study criteria. The questionnaire captured patient’s socio-demographic information and 
other relevant clinical/laboratory data. 
Data Analysis: The data was analysed using Epi info version 3.5.1 and Open Epi Version 2.2.1. 
Descriptive statistics for HIV-related ODs were carried out using percentages and frequencies 
tables for categorical variables and means (SD) or medians (IQR) for numerical variables. In 
univariate analysis, the Chi-square test was used to determine significance of association 
between OD and socio-demographic and clinical variables while the Student “t”-test was used to 
compare group means. Logistic regression model (multivariate analysis) was used to determine 
the independent risk factors for the occurrence of ODs using parameters that had a p-value of 
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<0.25 on univariate analysis. All reported p-values <0.05 were considered statistically 
significant. 
Results: The mean age of the participants was 41.1 ± 10.0 years; and females were in the 
majority (65.8%). Over 40% of them were rural dwellers, 50.4% belonged to the lower socio-
economic class, and 55% had a monthly household income less than 20,000 Naira. Fifty percent 
(50%) of them had advanced immunosuppression at first presentation. The median duration of 
HAART (3 years) paralleled the median duration of HIV diagnosis (3.4 years) and HAART 
adherence rate was 78%. The overall prevalence of ODs was found to be 22.4%. Among the 76 
patients diagnosed with ODs, the leading conditions were candidiasis (38.2%), TB (34.2%), 
dermatitis (25%), chronic diarrhoea (6.6%) and sepsis (6.6%).  The independent risk factors for 
the occurrence of ODs were household income less than 20,000 Naira (Adjusted odds ratio 
[AOR] = 2.4, 95% CI 1.1-5.1), HIV duration of less than 3 years (AOR= 2.1, 95% CI 1.1- 4.2), 
advanced WHO clinical stage at baseline (AOR= 8.1, 95% CI 4.0-16.4), baseline haemoglobin 
less than 10 g/dl (AOR= 2.9, 95% CI 1.3-56.1), current CD4 cell count less than 200 cells/µl 
(AOR= 3.0, 95% CI 1.14-6.2), and HAART non-adherence (AOR= 5.4, 95% CI 2.6-11.2). Past 
history of TB was found to be a strong predictor of TB (AOR= 5.3, 95% CI 1.4-20.2).  
Conclusions: Opportunistic diseases are common in patients receiving HAART in Nigeria and 
candidiasis and TB remain the leading conditions. Late presentation and HAART non-adherence 
are among the strongest risk factors for ODs in patients receiving HAART. Others include 
duration of HIV diagnosis less than 3 years, presence of anaemia at the time of first presentation 
and having a low CD4 cell count while on HAART. Beyond these clinical risk factors, poverty 
increases the risk of developing an OD during HAART and may emerge a strong determinant of 
HIV-related ODs in developing countries.  
Recommendations: A high index of suspicion for ODs remains necessary in HAART patients. 
Health education on HIV screening and early presentation should be intensified. PLHIV who are 
anaemic before commencement of HAART, those with low CD4 cell count despite HAART use, 
and low-income earners should become target groups for a more aggressive evaluation for ODs. 
Prophylaxis for TB and fungal infections in the absence of active disease should be widely 
implemented in developing countries. HAART adherence should be intensified.     
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CHAPTER 1 
        INTRODUCTION 
1.1 Background 
With the history of HIV/AIDS in Nigeria spanning well over three decades, it is not surprising 
that the number of people living with HIV (PLHIV) has substantially increased over these years. 
It is currently estimated that 3.3 million people are living with HIV in Nigeria with a total of 220, 
000 AIDS deaths in 2009 (UNAIDS, 2010). This currently places Nigeria as the country with the 
second largest number of PLHIV worldwide (FMOH, 2010). In response to the raging epidemic 
of HIV/AIDS, the Federal government of Nigeria in partnership with international collaborators 
established the national antiretroviral therapy (ART) programme in 2002 which led to increased 
access to HIV care and treatment (Odutolu, Ahonsi, Gboun & Jolayemi, 2006). The total number 
of PLHIV on ART steadily increased from 50,581 at the early stages of ART in Nigeria in 2005 
to 302,973 in 2009 (FMOH, 2010). So far, the efforts are still sub-optimal as only one-third of 
patients requiring treatment in Nigeria have access to ART (FMOH, 2010).  
The hallmark of HIV infection is immunosuppression which predisposes to unusual infections 
and malignancies which are generally known as opportunistic diseases (ODs) (Lederberger et al., 
1999). Globally, ODs are the major cause of morbidity and mortality in PLHIV (Sharma, 
Kadhiravan, Banga, Goyal, Bhatia & Saha, 2004; Komati et al, 2010). This is even more critical 
in sub-Saharan Africa (SSA) where the standard of living is generally poor and access to ART is 
still inadequate (UNAIDS, 2010). A striking feature of the reported clinical spectra of ODs in 
HIV/AIDS has been the contrasting findings from divergent socio-economic settings. In 
developed regions such as North America, Europe, and Australia, Pneumocystis carinii 
pneumonia (PCP), Kaposi’s sarcoma (KS), oesophageal candidiasis, cytomegalovirus (CMV)-
related disease and disseminated Mycobacterium avium complex (MAC) infection have each 
generally been reported in at least 20% of people with AIDS (Farizo, Bueliler & Chamberland, 
1992; Jougla et al., 1996; Dore, Li, McDonald & Kaldor, 2001). In developing regions such as 
SSA and Asia, where an estimated 90% of PLHIV reside, the predominant HIV-associated ODs 
include tuberculosis (TB), candidiasis, infective diarrhoea, meningitis, dermatitis and recurrent 
Herpes simplex infection (Hira, Dore & Sirisanthana, 1998; Holmes, Losina, Walensky, 
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Yazdanpanah & Freeberg, 2003). Some of the factors that may be contributing to this contrasting 
spectra of HIV-related ODs in developed and developing nations include socio-demographic, 
clinical and genetic factors as well as differences in HIV disease progression and infectious 
disease diagnostic capacity (Dore, Li,  McDonald & Kaldor, 2001; De Beaudrap et al., 2010). 
Since the advent of Highly Active Anti Retroviral Therapy (HAART), a significant decline in 
AIDS progression and ODs has been observed in both developed and developing regions 
(Ledergerber et al., 1999; Ives, Gazzard & Easterbrook, 2001; Seyler, Messou, Gabillard, 
Inwoley, Alioum & Anglaret, 2007; Zhou, Paton & Ditangco, 2007). However, significant 
differences still exist in the burden of ODs in the era of HAART in these two regions. Most of 
the evidence suggesting the decline in AIDS progression and ODs has come from high-income 
settings with relatively less burden of ODs in the pre-HAART era, early and widespread access 
to ART and sophisticated diagnostic tools. The findings of studies in high-income settings may 
not be generalizable to resource-limited settings. For example, ODs remain a big challenge in 
HIV/AIDS patients receiving ART in SSA (De Beaudrap et al, 2010).  In addition, there is 
insufficient knowledge about the factors that may be associated with the occurrence of ODs in 
HIV-infected populations receiving HAART in SSA.  
1.2 Problem statement and study rationale 
Opportunistic diseases constitute the major cause of morbidity and mortality in PLHIV even in 
the era of HAART (Sharma, Kadhiravan, Banga, Goyal, Bhatia & Saha, 2004; Komati et al., 
2010). This shortens the life expectancy of PLHIV. In addition, the high burden of ODs places 
additional economic strains on HIV care attributable to the additional cost of OD treatment. This 
is considered a significant burden for a developing nation like Nigeria.  
Moreover, geographical differences exist in the spectrum of ODs. An evidence-based 
identification and detailed assessment of the prevalent ODs in PLHIV in the era of HAART in 
order to define local priorities in HIV care and inform targeted expenditure on OD prophylaxis 
and treatment is therefore needed.  
In addition, timely intervention for ODs not only helps PLHIV to live longer, it also helps to 
prevent transmission of ODs such as TB to other people in the community (Saha et al., 2011). 
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Efforts to eliminate ODs in PLHIV cannot be successful if the risk factors for their occurrence 
are not well understood.  
Since the current spectrum of ODs in ART-experienced populations in Nigeria as well as the 
predicting factors remain largely undetermined, it will be difficult to fully assess the impact and 
sustained efficacy of ART in the country. This study therefore sought to contribute to filling 
some of this gap by investigating the prevalence of ODs in HIV-infected Nigerian adults on 
HAART and also determined some of the socio-demographic and clinical risk factors associated 
with their occurrence.   
 
1.3 Description of research setting 
This study was carried out at the Federal Medical Centre (FMC), Owerri, Imo State, South-east 
Nigeria. This is a tertiary health institution that provides services to both urban and rural 
populations in Imo State and some other neighbouring towns in other States in South-east 
Nigeria especially Abia and Anambra States. Owerri is the capital of Imo State and is surrounded 
by other local government areas that are predominantly rural settlements. The predominant 
ethnic group is Igbo and is also the local language spoken. English language is officially spoken 
among literate groups in public and corporate private sectors. In Owerri town, people that belong 
to non-Igbo ethnic groups are very much in the minority and include major ethnic groups such as 
Hausa and Yoruba, as well as other minor ethnic groups such as Efik/Ibibio, Edo, and Ijaw. The 
major occupations of the people of Owerri are trading and civil service. Farming is also common 
especially on the outskirts of the town and in the surrounding rural settlements. Imo state has a 
population of 3.9 million (NPC, 2006). The prevalence of HIV in Imo State is 4.6% which is the 
same as the national HIV prevalence of 4.6% (FMOH, 2010). 
The HIV clinic in FMC, Owerri which is otherwise called “Heart-to-Heart Centre” is a Family 
Health International (FHI)-facilitated HIV care and treatment centre that provides ambulatory 
services for about 5,000 patients out of whom approximately 2,000 adults (female to male ratio 
of 2:1) were receiving HAART as at September 2011 (Personal communication with the HIV 
clinic principal investigator, Dr Eugenia Ofondu, 5
th
 September, 2011). The clinic has three 
sections: adult, paediatric, and prevention of maternal-to-child transmission sections. This study 
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was carried out in the adult clinic. In addition, FMC, Owerri has admission facilities for the 
treatment of ill HIV-infected patients requiring in-patient care under the care of specialist 
consultant physicians including an infectious diseases specialist, a dermato-venereologist, and a 
respiratory physician. The services of the HIV clinic include HIV counseling and testing, clinical 
supportive care of HAART-naïve patients, antiretroviral and OD drug treatment, and laboratory 
support services. HIV screening/confirmation, most laboratory investigations, ART, and 
cotrimoxazole prophylaxis, are provided free of charge.  
The HIV clinic has a monitoring and evaluation section whose responsibilities include receiving 
notification from clinicians on patients with opportunistic diseases, reporting of adverse drug 
reactions, identification and tracking of treatment defaulters as well as identification of patients 
with treatment failure. Although these records are available both for patient management and 
research, most of the monitoring and evaluation activities focus on individual patients such that 
cohort monitoring is not routinely done at the centre.  
1.4   Study aims and objectives 
1.4.1 Aim 
 To investigate the epidemiology of opportunistic diseases (ODs) in the era of HAART at 
the FMC in Owerri, Nigeria. 
1.4.2 Specific objectives 
 To estimate the prevalence of ODs in HIV-infected patients receiving HAART at FMC in 
Owerri, Nigeria. 
 To describe the socio-demographic and clinical characteristics of patients on HAART 
experiencing ODs at FMC in Owerri, Nigeria. 
 To determine independent risk factors for occurrence of ODs in patients on HAART at 
FMC in Owerri, Nigeria. 
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         CHAPTER TWO 
                        LITERATURE REVIEW 
2.1 Global epidemiology of HIV/AIDS 
Globally, 34 million people are estimated to live with HIV/AIDS and about 2 million people die 
annually from the disease with the most severe effects occurring in young adults in their 
economically productive years (UNAIDS, 2011). The majority of the new HIV infections (2.7 
million) continue to occur in SSA (UNAIDS, 2011). Africa with just 10% of the world 
population is home to 70% of PLHIV worldwide (UNAIDS, 2011). The number of annual 
AIDS-related deaths worldwide is steadily decreasing from the peak of 2.1 million in 2004 to an 
estimated 1.8 million in 2010 (UNAIDS, 2011). The decline reflects the increased availability of 
ART, as well as care and support for PLHIV. However, the pattern of decline has significant 
regional variations (UNAIDS, 2011). In North America as well as Western and Central Europe, 
deaths due to AIDS began to decline soon after ART was introduced in early/mid 1990s while 
AIDS-related mortality only began to decline in SSA and the Caribbean in 2005 (UNAIDS, 
2011). In Eastern Europe and Central Asia, the number of people dying from AIDS-related 
causes increased more than 10-fold between 2001 and 2010. In the same period, the number of 
people dying from AIDS-related causes increased by 60% in the Middle East and North Africa  
and more than doubled in East Asia (UNAIDS, 2011).  
2.2 Natural history of HIV infection 
Following HIV infection, there is usually a 2-4 week serologic and clinically silent period known 
as serologic latency or window period. Subsequently, a seroconversion or primary illness in the 
6-8weeks following infection ensues, which may present with a flu-like illness. This often lasts 
for about three weeks and is usually associated with “recovery” (Fauci & Lane, 2005). At this 
stage, there is a drop in the CD4 cell count which reflects a compromise of the immune system. 
The primary infection is followed by a prolonged period
 
of clinical latency during which the 
patient is often asymptomatic and the CD4 cell count is usually above 500 cells/µl (Fauci & 
Lane, 2005). As HIV infection progresses, the patient develops an array of symptoms and signs. 
During this period the CD4 cell count falls continuously and when it is below 200 cells/µl, the 
risk of developing ODs becomes high. AIDS represents the late clinical and immunological stage 
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of HIV disease. With advanced clinical disease death often ensues within a few months to years. 
The mean time to the development of AIDS is about 10 years in most reports (Fauci & Lane, 
2005). However, there are some reports of a faster progression to AIDS in sub-Saharan Africa 
(Morgan & Whitworth, 2001).   
2.3 Overview of progress in antiretroviral therapy 
Although HIV was first discovered in the early 1980s (Fauci & Lane, 2005), ART was only 
introduced in Europe and North America in early/mid 1990s and progressively became available 
with easy access and sustained coverage within five years (UNAIDS/WHO, 2006). Although 
ART gradually trickled into low and middle-income countries in the late 1990s, established 
access to ART was only witnessed in early 2000 and access to ART has continued to be scaled 
up since then (UNAIDS/WHO, 2006). From a starting point of 400,000 people receiving ART in 
low and middle-income countries in December 2003, about 6.7 million people were receiving 
treatment by December 2010 (UNAIDS, 2011). However, this is still sub-optimal as the 
estimated ART coverage among adults and children in low- and middle-income countries is just 
about 47% (UNAIDS, 2010).  
The Federal Government of Nigeria initiated the national ART programme in January 2002 as 
part of an expanded response to care and support for PLHIV. Under this programme, 10,000 
adults and 5,000 children were treated with a 3-drug ART combination. At onset, the programme 
involved 25 treatment centres across the 6 geopolitical zones of the country and was subsidized 
at a cost of US$10 per month for each patient (Idigbe et al., 2005). Unfortunately, in 2004 the 
programme suffered a major setback when it was hit by a shortage of drugs which lasted for 
about three months (Monjok, Smesny, Okokon, Mgbere, & Essien, 2010). During this time, 
many patients were off drugs or staggered their dosages for the three months, which led to a 
structurally-induced adherence problem. The programme subsequently resumed when US$ 3.8 
million worth of drugs were delivered. Another programme was started in 2006 with the goal of 
providing drugs at no cost to about 250,000 HIV-positive patients. Nevertheless, Nigeria remains 
among the countries where HIV treatment coverage is far from desirable. At the end of 2009, 
only about one third of people with advanced HIV infection were on ART in Nigeria (FMOH, 
2010). 
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2.4 HIV/AIDS and opportunistic diseases 
Opportunistic diseases refer to unusual infections and malignancies which may develop in 
PLHIV in the course of their disease (Lederberger et al., 1999). Overwhelming evidence 
indicates that the overall incidence of ODs in PLHIV increases with the degree of 
immunosuppression as reflected by the CD4 cell count (Yazdanpanah et al., 2001, Salami, 
Olatunji & Oluboyo, 2006). The level of immunity of an individual can be assessed by 
determining the CD4 cell count which is an expression of the number of immune cells present. In 
healthy individuals with adequate immunity, the CD4 cell count is variable but ranges between 
600 and 1,500 cells/µl. As shown in Fig. 2.1, the risk of specific HIV-related OD varies with the 
degree of immunosuppression (Crowe, Carlin, Stewart, Lucas & Hoy, 1991; Morgan & 
Whitworth, 2001). For example, infections with herpes viruses, candida, or pyogenic bacteria 
may occur in asymptomatic persons with moderate immunosuppression whereas the risk for PCP 
markedly increases when the CD4
 
count is less than 200 cells/µl
 
(Masur et al., 1989; Crowe, 
Carlin, Stewart, Lucas & Hoy, 1991). MAC infection, CMV disease and non-Hodkin’s 
lymphoma typically develop when the CD4 cell
 
count is less than 100 cells/µl
 
(Masur et al., 
1989; Crowe, Carlin, Stewart, Lucas & Hoy, 1991). Other conditions such as TB and KS may be 
experienced at any level of CD4 cell count (Morgan & Whitworth, 2001; Nwuba, Okonkwo, 
Abolarin, Ogbu & Modebelu, 2012). A large percentage of PLHIV experience several ODs 
before death and their mortality is ultimately attributable to one of these events (Chan, Neaton, 
Saravolatz & Osterberger, 1995; Sharma, Kadhiravan, Banga, Goyal, Bhatia & Saha, 2004; 
Losina et al., 2006).  
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Fig 2.1: Relationship between specific HIV-related opportunistic diseases and CD4 cell   
   count (Adapted from Wilcox & Saag, 2008) 
 
 
A striking feature of the reported clinical profile of ODs in HIV/AIDS has been the contrasting 
findings from high and low-income countries. In a survey of 6,682 HIV-infected patients 
spanning 1990 to 1994 in the United States, 1,883 died from ODs during the follow up. The most 
common ODs experienced were PCP (45%), MAC infection (25%), HIV wasting syndrome 
(25%), bacterial pneumonia (24%), CMV disease (23%) and candidiasis (22%) (Chan, Neaton, 
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Saravolatz & Osterberger, 1995). It was observed that more diseases varied by geographical 
location than by demographic characteristics or risk behaviour of the patients. Similarly, in 
France, Jougla et al. (1996) found that the most frequently reported ODs in AIDS patients were 
toxoplasmosis (37%), CMV disease (37%), PCP (29%), KS (28%), HIV encephalopathy (27%), 
invasive candidiasis (23%), Herpes simplex virus infection (18%) and MAC infection (17%). 
Tuberculosis was relatively less common occurring in only 11% of the population. Unlike the 
report of Chan et al. (1995), the authors further observed that the diseases varied by HIV risk 
behaviour. Few differences in the pattern of ODs were observed by gender.  
Contrary to the findings of studies in developed countries, TB tops the list of HIV-associated 
ODs in most low and middle-income countries of SSA and South-East Asia (Holmes, Losina, 
Walensky, Yazdanpanah & Freeberg, 2003; Singh, Bairy & Shivananda, 2003; Dhungel, 
Dhungel, Easow & Singh, 2008). In India, the commonly reported ODs were candidiasis (59%), 
TB (56%), and cryptosporidium diarrhoea (47%) (Singh, Bairy & Shivananda, 2003). 
Pneumocystis carinii pneumonia (7%), CMV disease (6%), Herpes simplex infection (3%) and 
toxoplasmosis (4%) were less common.  
A more recent study in India in which 90% of the participants were not on ART made similar 
observations in the spectrum and rate of ODs (Ghate et al., 2009). Tuberculosis was the most 
common OD with an incidence of 15.4 per 100 person-years, followed by oral candidiasis 11.3 
per 100 person-years, and herpes zoster 10.1 per 100 person-years. Cryptococcal meningitis was 
far less common at 1.7 per 100 person-years. In their study, patients with CD4 cell counts of less 
than 200 cells/µl were six times more likely to develop ODs compared to those with CD4 cell 
counts more than 350 cells/µl (p<0.001). 
Contrarily, TB, diarrhoea, and oesophageal candidiasis have been shown to have relatively lower 
prevalence rates in some HIV-infected patients in rural Thailand, another developing nation. 
Inverarity, Bradshaw, Wright and Grant (2002) observed that 32% of HIV-infected patients 
presenting for the first time between 1997 and 2000 in a mission hospital in rural Thailand had 
AIDS-defining ODs. The reported ODs included cryptococcal meningitis (15%), bacterial 
pneumonia (12%), extrapulmonary TB (12%), PCP (7%), cerebral toxoplasmosis (4%), 
pulmonary TB (3%), oesophageal candidiasis (2%), and sepsis (2%). However, the authors 
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opined that it is possible that TB and sepsis were under-diagnosed and further highlighted the 
need for improved diagnostic facilities and validation of clinical algorithms. 
In a comprehensive review of HIV-related ODs in SSA using data from 18 countries [Nigeria not 
inclusive], the prevalence of common ODs were as follows: TB (27-61%), candidiasis (14-67%), 
parasitic chronic diarrhoea (6-42%), Streptococcus pneumoniae infections (25-31%), 
cryptococcal meningitis (0-50%), and PCP (1-11%) (Holmes, Losina, Walensky, Yazdanpanah 
& Freeberg, 2003). The authors acknowledged that the constraints of data on the burden of HIV-
related OD in SSA include the lack of longitudinal studies with long follow-up periods, inability 
to estimate the time of seroconversion, and the variable OD diagnostic criteria occasioned by 
limited diagnostic facilities.  
In a 2 year retrospective analysis of HIV-infected patients in Ilorin, North-central Nigeria, 
Salami, Olatunji and Oluboyo (2006) found that ODs occurred in 68.6% of the patients. 
Tuberculosis (pulmonary and extra-pulmonary), HIV encephalopathy, cryptococcal meningitis, 
KS and candidiasis (pulmonary) topped the list. It was also reported that the risk of death was 
four-fold higher in individuals with ODs. In another survey in North-central Nigeria, 56.7% of 
HIV-infected patients were found to present late in terms of stage of immunosuppression at first 
hospital visit. The commonest ODs among them were TB (61.8%), candidiasis (25%), 
septicaemia (21%), chronic diarrhea (18.4%), cryptococcal meningitis (9.2%), HIV 
encephalopathy (7.8%), and KS (7.8%) (Daniyam, Iroezindu, Shehu, Essien, Sati & Agaba, 
2011). A multi-centre study in North-eastern Nigeria investigated ODs in HIV-infected 
populations and also found a high prevalence of 61.7% (Saidu, Bunza, Abubakar, Adamu, Ladan 
& Fana, 2009). Intestinal parasitic infections occurred in 28.5% of the participants, sexually 
transmitted infections (STI) in 22.1%, gastrointestinal candidiasis in 8.6% and TB in 6.7%. 
Despite the fact that these studies carried out in Nigeria are recent, none of them focused on 
HIV-related ODs in HAART patients. Although the overall prevalence of OD reported in these 
studies from Nigeria are similar, the relatively low burden of TB as an HIV-associated OD reported 
by Saidu et al. (2009) in North-eastern Nigeria is in sharp contrast with that documented in North-
Central Nigeria by Salami et al. (2006) and Daniyam et al. (2011) where TB was the commonest 
HIV-associated OD. This difference may be due to a number of reasons.  The studies by Salami et al. 
(2006) and Daniyam et al. (2011) were each carried out in one centre compared to that of Saidu et al. 
(2009) which was a multi-centre study with a sample size nearly double that of Salami et al. (2006) 
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and eight times larger than that of Daniyam et al. (2011). In addition, the differences in the age, 
immune status and TB exposure risks of their study populations could have also contributed.  
There is paucity of data on the burden of some ODs such as PCP and MAC in Nigerian HIV-infected 
populations. While this may suggest their relative lower burden in the country, the fact that the 
appropriate diagnostic facilities for these conditions are generally lacking in the country should be 
borne in mind before drawing strong conclusions regarding them.  
A possible argument at this point is to verify if environmental or genetic factors have any impact 
on the spectrum of HIV-related ODs. A review of the profile of ODs in people living in Australia 
was carried out to study the effect of country/region of origin (Dore, Li, McDonald & Kaldor, 
2001). Tuberculosis prevalence was only 1% for both Australian and other industrialized 
country/region born AIDS patients. In contrast, TB prevalence was 10% in Asia-Pacific and 23% 
in SSA born AIDS patients. Prevalence of PCP was 27-34% and clearly the most commonly 
diagnosed condition in all country/region of birth categories except SSA. AIDS cases born in SSA 
had an increased risk of TB (OR=18.7; 95% CI= 9.2–38.2) and cryptococcosis (OR = 2.4; 95% CI= 1.1–
5.4), but a decreased risk of oesophageal candidiasis (OR=0.3; 95% CI= 0.1–0.8) and PCP (OR=0.5; 95% 
CI= 0.3–0.9) compared to AIDS cases born in Australia. Tuberculosis risk was also elevated among 
AIDS cases born in Asia-Pacific (OR=9.6; 95% CI= 5.3–17.5) and other developing countries/regions 
(OR= 3.1; 95% CI= 0.9–10.4). The risk of AIDS-related ODs was similar for AIDS patients born in 
Australia and other industrialized country regions.  
Del-Amo et al. (1996) also compared the spectrum of disease and severity of immune deficiency 
in HIV-infected African and non-African patients in London. HIV-infected African patients 
presented at lower levels of CD4 cell count and at a more advanced clinical stage of disease. 
Tuberculosis accounted for 27% of the initial episodes of AIDS-related OD in Africans but 5% 
in non-Africans while PCP was the initial AIDS-related condition in 34% of non-Africans but 
17% for Africans.  
While the studies by Dore et al. (2001) in Australia and Del-Amo et al. (1996) in London 
reviewed above made their observations based on racial disparities, another report by 
Yazdanpanah et al. (2001) highlighted in-country regional differences in the burden of HIV-
related OD in France among people who did not have racial disparity. Their study population 
comprised HIV-infected persons from two different centres in Tourcoing and Aquitaine. They 
had similar populations including men who have sex with men (MSM), and injection drug users. 
 
 
 
 
 12 
 
Their findings corroborated the widely-recognised observation that the incidence rates of the 
various ODs including PCP, CMV and toxoplasma encephalitis were significantly higher in 
participants with severe immunosuppression. In addition, they observed that the incidence of 
PCP (RR=1.9, 95% CI: 1.1-3.0) and CMV infection (RR=2.2, 95% CI: 1.4-3.4) were 
significantly higher in Tourcoing than in Aquitaine which was not attributable to differences in 
level of immunity between PLHIV in the two regions.  
 In summary, although the immunological stage of HIV infection is a strong predictor of the 
occurrence of ODs, it may not be out of place to suggest that the predominance of TB in PLHIV 
in SSA and Asia is still a reflection of the poverty-driven higher TB burden in the general 
population (Singh, 2002). This becomes a good justification to identify the clinical as well as the 
socio-demographic risk factors for the occurrence of ODs in a given HIV-infected population.  
 
2.5 HAART and opportunistic diseases 
 
Since the advent of HAART, a significant decline in AIDS progression and the incidence of ODs 
have been observed in both developed and developing regions (Ledergerber et al., 1999; Hung & 
Chang 2004; Sun et al., 2006; Seyler, Messou, Gabillard, Inwoley, Alioum & Anglaret, 2007; 
Zhou, Paton & Ditangco, 2007; Ives, Gazzard & Easterbrook, 2011). In fact, according to Kaplan 
et al. (2000), “the incidence of nearly all AIDS-defining opportunistic infections decreased 
significantly in the United States during 1992-1998”; an observation that was attributable to the 
introduction of HAART. Kaplan et al. (2000) further observed that the decline for specific ODs 
was even more impressive after longer duration of HAART in US cohorts. In their report, the 
incidence of PCP declined by 21.5% per year in 1996-1998 compared with 3.4% decline per year 
in 1992-1995 (p<0.001); MAC disease declined by 39.9% per year in 1996-1998 compared to 
4.7% in 1992-1995 (p<0.001), while the incidence of oesophageal candidiasis declined by 16.7% 
per year in 1996-1998 compared to 0.2% in 1992-1995 (p<0.001). In another report from United 
States by Pallela et al. (1998), the incidence of any of the three major ODs (PCP, MAC disease, 
and CMV retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years 
by mid-1997.  
Such patterns of decline in AIDS-related ODs have also been reported in other cohorts in 
Canada, Western Europe, and Australia (Brodt, Kamps, Gute, Knupp, Staszewski & Helm, 1997; 
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Forest et al., 1998; Barbiker et al., 2002). In a multinational cohort study involving 6,941 PLHIV 
in Australia and ten European countries, when comparing the periods 1997-2001 and 1994-1996, 
there were significant HAART-induced decreases in various ODs including candidiasis from 
17.0% to 5.7%; cryptosporidiosis from 3.1% to 0.2%; cytomegalovirosis from 5.9% to 0.6%; 
PCP from 17.0% to 4.4%; toxoplasmosis from 3.4% to 1.4% and TB from 6.4% to 2.6% 
(Barbiker et al., 2002). Forest et al. (1998) in Canada, documented that the rate of decline in 
AIDS-related major ODs was highest for PCP, at 5 cases per 1,000 every 6 months from 1994 to 
1996 (p=0.004). It was reported in Germany that the incidence of AIDS-related ODs had 
declined by more than 70% between 1992 and 1996 (Brodt, Kamps, Gute, Knupp, Staszewski & 
Helm, 1997).   
In developing countries, most of the research assessing the impact of HAART on ODs lags 
behind studies in Western countries by about 5-10 years which is probably reflective of the time 
lag in accessibility and availability of HAART in the two socio-economic environments. 
Nevertheless, decline in the burden of ODs has also been observed in developing nations (Hung 
& Chang 2004, Sun et al., 2006; De Beaudrap et al., 2010). In a cohort of 1,044 Taiwanese 
patients accessing HAART over a 10 year period spanning 1994 to 2004, the rate of AIDS-
related ODs  dropped from 77.7% at enrolment (i.e. pre-HAART) to 56.3% three months after 
the introduction of HAART and further gently declined to 47.6% within 3-12 months of HAART 
(Sun et al., 2006). The authors observed that the spectrum of ODs were similar in the three study 
periods (pre-HAART, early HAART era and later HAART era) with candidiasis, and TB being 
among the commonest conditions. In India, Srirangaraj and Venkatesha (2011), reported a 
drastic reduction of OD events from 68.5% to 8.3% after 6 months of HAART in a prospective 
observational cohort study of 108 HIV-infected patients accessing care over a one year period 
between 2006 and 2007. Interestingly, the pre-HAART and post-HAART spectra of ODs in the 
study of Srirangaraj and Venkatesha (2011) and that of Sun et al. (2006) were similar so cannot 
be the reason for the variable rates of OD decline reported between the two studies. While the 
study in India was carried out during a period in which access to ART in Asia was already well 
established, the report from Taiwan included people who were on treatment in the early years of 
ART and this may account for the differences in the rates of decline of HIV-related ODs 
attributable to HAART in the two Asian populations. Nevertheless, the fact that the report from 
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Taiwan had a sample size ten times larger than the Indian population and followed up their 
cohort for a much longer duration may readily explain the differences in the rates of OD decline 
observed.  
In Brazil, South America, it has been demonstrated that HAART significantly reduced the rates 
of ODs, hospitalizations and mortality (Candiani, Pinto, Cardoso, Carvalho, Dias, Carneiro & 
Goulart, 2007). In that study, 371 HIV-infected Brazilian patients were observed from 1989 to 
2003. The overall rate of ODs declined from 18.3 per 100 persons-years in the pre-HAART era 
to 2.6 per 100 persons-years in the post-HAART era. In multivariate analysis, the risk of 
developing an OD was 5.4 times greater before HAART.  
The impact of HAART on AIDS-related ODs may not have been sufficiently explored in SSA 
partly because the majority of the HIV-infected populations requiring ART are yet to have access 
to it (UNAIDS, 2011). In Cote d’Ivoire, West Africa, Losina et al. (2007) demonstrated the 
independent effect of HAART in the reduction of severe ODs and death. The authors observed a 
CD4-independent reduction in risk of severe OD, death, or both for patients on HAART. This 
independent effect of HAART was found to be greater when patients were on HAART for more 
than 6 months. In Senegal, West Africa, De Beaudrap et al. (2010) documented that the 
incidence of AIDS-related ODs declined from 20.5 per 100 person-years during the first year of 
observation on HAART to 4.3 per 100 person-years during the fourth year but increased 
afterwards by 5% per month. The increase in the burden of ODs noticed after the fourth year of 
HAART makes the findings of this study peculiar compared to the others considering that studies 
that even followed PLHIV for longer durations of HAART in Western countries and Asia did not 
make such observations. This makes it imperative to investigate other HAART-related and non-
HAART related factors that may compromise the long-term benefits of HAART in SSA where 
socio-cultural determinants of health play a strong role.  
At this point, it is also useful to say that while prevalence and incidence studies can readily be 
used to investigate the burden of ODs in patients receiving HAART, one notable difference 
between the two approaches is that incidence studies make it possible to compare the burden of 
ODs at specified times in the study to the pre-HAART rates for the same population. This 
explains why De Beaudrap et al. (2010) were able to observe both periods of decline and 
increase in ODs in their cohorts.   
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Despite the well-documented efficacy of HAART in reducing the incidence of HIV-related ODs, 
the spectrum (relative frequencies) of common ODs have not changed significantly after 
introduction of HAART and neither has the burden of ODs changed by the same rates  across 
various regions (Forest et al., 1998; Ledergerber et al.; 1999; Sun et al., 2006; De Beaudrap et 
al., 2010). So far, most of the evidence suggesting progressive decline has come from high-
income settings with relatively less burden of ODs in the pre-HAART era, early and widespread 
access to ART and sophisticated diagnostic tools (Ledergerber et al., 1999; Ives, Gazzard & 
Easterbrook, 2011). Opportunistic diseases exemplified by TB and candidiasis remain a big 
challenge in HIV/AIDS patients receiving HAART especially in SSA (De Beaudrap et al., 
2010). For example, in 2,605 HIV-infected patients on HAART in South Africa followed up for 
30 months, ODs manifested in 47.6% of the patients in whom mortality was recorded while on 
HAART (Mzileni, Mbenza & Chephe, 2008). Hence, it is of immense public health importance 
to further explore the burden of HIV-associated ODs and the associated risk factors in the era of 
HAART in SSA. 
 
2.6 Risk factors for opportunistic diseases in patients receiving HAART 
A number of studies have investigated the risk factors associated with the occurrence of ODs in 
patients receiving HAART. In the Swiss cohort study, Ledergerber et al. (1999) reported that the 
risk of developing an OD was highest during the initial months of HAART. Baseline CD4 cell 
count as well as subsequent CD4 cell counts and HIV viral load levels after commencement of 
HAART were strong predictors of the development of ODs.  In the United States, decreasing 
CD4 cell count and increasing HIV viral load were the strongest predictors of the occurrence of 
ODs in adults and adolescents receiving HAART (Kaplan, Hanson, Jones & Dworkin, 2001). In 
several studies, longer duration of HAART has also been associated with lesser risk of ODs 
(Brodt, Kamps, Gute, Knupp, Staszewski & Helm, 1997; Hung & Chang 2004; Losina et al., 
2007). This observation is however partly contradicted by De Beaudrap et al. (2010) who 
observed increased OD risk beyond four years of HAART after an initial decline before this 
time. 
According to Manosuthi et al. (2007), the independent risk factors for developing ODs in adult 
Thai HIV-infected patients were baseline CD4 ≤50 cells/µl, male gender and low body weight. 
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In another Asian population, CD4 cell count during HAART was found not to be a significant 
predictor of ODs with the exception of TB and candidiasis (Srirangaraj & Venkatesha, 2011). 
The authors acknowledged that this was rather unusual and attributed this observation to the fact 
that all their patients were on cotrimoxazole prophylaxis which possibly prevented the 
occurrence of ODs in HAART-experienced patients who had low CD4 cell count.  
In an evaluation of HIV-infected patients on HAART in South Africa, independent risk factors 
for TB were low CD4 cell count, high baseline viral load, low haemoglobin, low body mass 
index as well as male gender (Komati et al. 2010). In another study in South Africa, the 
occurrence of TB in patients receiving HAART was independently associated with baseline 
characteristics including CD4 cell count <100 cells/µl, WHO stage 3 or 4 disease and age less 
than 33 years (Lawn, Badri & Wood, 2005). Contrary to most available evidence, HIV viral load 
was not significantly associated with the risk of developing TB in this study. In addition, the risk 
of TB was not associated with a past history of TB, low socioeconomic status or gender (Lawn, 
Badri & Wood, 2005). The reasons for the disparity between the observations of Lawn et al. 
(2005) and those of Komati et al. (2010) may be partly related to time frame. While the 
population studied by Lawn et al. (2005) included PLHIV in the early stages of HAART when 
access to treatment was quite poor in SSA, Komati et al. (2010) focused on HAART-experienced 
PLHIV between 2004 and 2007.  
So far, it may be appropriate to observe that only few studies such as those of Lawn, Badri and 
Wood (2005), Manosuthi et al. (2007), and Komati et al. (2010) considered the association 
between socio-demographic factors and development of ODs. Incidentally, these studies are all 
conducted in developing countries. The emphasis has virtually been on clinical parameters 
especially CD4 cell count and HIV viral load with little regard for socio-demographic factors. In 
SSA where socio-economic factors are far from desirable, ignoring their role in critical health 
issues such as ODs in HIV-infected patients on HAART will be a fundamental oversight. 
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CHAPTER THREE 
METHODOLOGY 
3.1 Study design 
This was a quantitative, cross-sectional descriptive and analytical study. It involved the 
description of the prevalence of opportunistic diseases (ODs) in HIV-infected patients receiving 
HAART in Owerri, Nigeria. Analysis of the risk factors for the occurrence of the ODs was also 
carried out.  
The possibility of a cohort study in order to assess incidence of ODs rather than prevalence was 
considered for this study but some of the anticipated drawbacks made an alternative study design 
difficult. For example, a retrospective analysis using already existing records on ODs would 
have been less capital-intensive. However, it may limit the strength of some of the findings 
considering that the privilege of employing a rigorous process in arriving at definitive OD 
diagnosis will be lost. On the other hand, embarking on a prospective cohort study was not 
considered feasible in view of the limited time and resources available for the mini-thesis.  
3.2 Study population 
The study population comprised of adult HIV-infected patients 15 years and above who were on 
HAART at the HIV clinic of the FMC, Owerri, South-east Nigeria. Patients included in the study 
were those whose HIV positive status was confirmed by Western blot, and they consented to the 
study. In addition, they were required to have received HAART for a minimum of 12 weeks. 
This was to ascertain that they had received HAART long enough to have achieved virological 
suppression and immune reconstitution. HAART-naïve patients and those currently manifesting 
an OD whose onset ante-dated the commencement of HAART were excluded from the study. 
3.3 Sample size  
The sample size was calculated using the formula for prevalence studies proposed by Krejcie & 
Morgan (1970):  
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Where:  
n= minimum sample size 
χ2 = the table value of Chi-square at 1 degree of freedom for 95% confidence interval = 3.84 
N= population size i.e. total number of adult patients on HAART at FMC, Owerri= 2,000 
P = prevalence of ODs in a previous study in South Africa = 47.6% (0.467) 
       (Mzileni, Mbenza & Chephe, 2008)  
ME = Desired margin of error (i.e. level of precision) = 5% (0.05) 
 
This formula estimated a minimum sample size of 322 patients at a 95% confidence interval and 
5% precision based on prevalence of ODs of 47.6% in the mortality data of HIV-infected 
patients on HAART in a previous study in South Africa (Mzileni, Mbenza & Chephe, 2008) 
using a population of approximately 2,000 HIV-infected adults currently on HAART at the study 
site (FMC, Owerri HIV clinic data office records). The study in South Africa was used due to 
lack of such data from Nigeria and neighbouring countries. However, to accommodate events 
such as poorly completed questionnaires and incomplete results, additional 10% of the minimum 
sample size was enrolled which increased the sample size to 354.  
To further verify the sample size calculation, a sample size table which employed this formula 
with various levels of precision, population size and the related sample size is shown in appendix 
9 (The Research Advisors, 2006). 
3.4 Sampling procedure 
After applying the exclusion criteria, a systematic sampling method with a random starting point 
was used to recruit 354 patients from a population of 1,560 HIV-infected patients on HAART 
who were scheduled to visit the clinic within the 3 months of data collection. A sample interval 
of 3 was used such that every third person was selected. A random starting point between 1 and 3 
was selected and subsequently every third person was selected until the required sample size of 
354 was attained.  
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3.5 Opportunistic disease diagnostic criteria 
The diagnosis of opportunistic diseases was made according to standard guidelines where 
possible and facilities available. Where diagnosis was entirely based on clinical grounds, two 
independent physicians involved in HIV care and management were required to have the same 
assessment before such diagnosis was accepted.   
Candidiasis was detected by clinical examination followed by isolation of the yeasts from 
oropharyngeal or vaginal swabs.   
Tuberculosis screening was offered to the patients based on a TB screening algorithm for HIV-
infected patients (Cain et al., 2010). Tuberculosis diagnostic algorithm was subsequently used to 
evaluate patients with a positive TB screening response (i.e. patients who reported having at least 
one of the 3 screening symptoms of cough of any duration, fever of any duration or night sweats 
of ≥3 weeks in the preceding 4 weeks).  
Pulmonary TB was defined as presence of cough with or without fever, weight loss, night sweats 
or haemoptysis and demonstration of acid fast bacilli (AFB) in two or more sputum samples 
and/or chest X-ray features compatible with TB (Sharma, Kadhirava, Banga, Goyal, Bhatia & 
Saha, 2004; Ghate et al., 2009).  
Extra-pulmonary TB was diagnosed as clinical evidence suggestive of TB without features of 
pulmonary involvement followed by histology of lymph node biopsy [for TB lymphadenitis], or 
followed by findings of exudative pleural effusion accompanied by clinical response to anti-
tuberculous drugs [for pleural TB], or followed by ultrasonography of the abdomen for evidence 
of lymph nodes accompanied by clinical response to anti-tuberculous drugs [for abdominal TB] 
(Ghate et al., 2009; Sharma, Kadhirava, Banga, Goyal, Bhatia & Saha, 2004). 
Disseminated TB was defined as clinical features suggestive of TB with concurrent involvement 
of at least two non-contiguous organs, with positive sputum smear and/or histopathological 
and/or radiological evidence of TB (Sharma, Kadhirava, Banga, Goyal, Bhatia & Saha, 2004). 
For patients with negative sputum AFB despite strongly suggestive clinical and/or radiological 
features and patients whose diagnosis of extrapulmonary TB was not based on definitive tests 
such as histology, further supportive laboratory evidence especially elevated erythrocyte 
sedimentation rate (ESR), followed by clinical response to anti-tuberculous drugs at least in the 
intensive phase of treatment was further required before diagnosis of TB was accepted. For any 
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patient in this category whose anti-tuberculous drug response was not ascertained, the diagnosis 
of TB was not upheld.   
Cryptococcal meningitis was diagnosed based on clinical evidence of meningitis with 
demonstration of cryptococcal yeast cells in the cerebrospinal fluid by Indian ink staining.  
Chronic diarrhoea was initially diagnosed based on history and the responsible aetiologic agent 
was then isolated by appropriate stool analysis.  
Sepsis was defined as the presence of ≥2 of the following: body temperature >38°C or <36°C; 
pulse rate >90 beats/min, respiratory rate >20 breaths/min, white cell count >12 X 10
9
/l or <4 X 
10
9
/l or >10% immature (band) forms, in the presence of infection (Russell, 2006). The 
responsible aetiologic organism for the sepsis was subsequently identified by blood culture.  
Bacterial pneumonia was diagnosed as clinical evidence of pneumonia with supportive chest X-
ray infiltrates and positive sputum bacteriological test.  
Kaposi’s sarcoma was confirmed by histology of tissue biopsy obtained from the skin lesion 
following clinical evaluation. 
Herpes zoster was diagnosed based on clinical evidence of prototypic painful skin eruptions with 
characteristic dermatomal distribution. 
Genital herpes was diagnosed based on clinical evidence of painful genital ulcer preceded by 
vesicles with negative veneral disease research laboratory (VDRL) test for syphilis.  
Genital wart was diagnosed based on the characteristic lesion on clinical examination.  
 
3.6 Other case definitions  
3.6.1 Socio-economic classification 
The socio-economic class of the family was assessed using the father’s occupation/income and 
the maternal educational attainment as recommended for Nigeria by Olusanya, Okpere & 
Ezimokhai (1985). This method stratifies socio-economic class into five classes I to V. Class I 
represent the upper cadre, classes II and III the middle cadre while classes IV and V are the 
lower cadre. The father’s occupation had a cumulative score of 3 while the mothers’ educational 
attainment had a cumulative score of 2. The total score from both parameters placed each 
participant in the respective classes. The scoring system is described below: 
Father’s occupation:  
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Score 1– professionals, top civil servants, politicians, high level businessmen.  
Score 2– middle level bureaucrats, skilled artisans and well to do traders. 
Score 3– unskilled workers and those whose income is at or below the national minimum wage.  
Mother’s educational attainment:  
Score 0 – tertiary education – university, polytechnic (higher national diploma). 
Score 1- secondary education– secondary school, college of education, ordinary diploma 
Score 2– primary education or no schooling.  
This classification system is judged relevant in developing countries like Nigeria where most 
mothers are uneducated considering that mother’s education has been shown to be positively 
associated with health care knowledge and heath seeking behaviour in the family irrespective of 
household income (Otta, 1992; Alaka & Stephenson, 2005).  
 
3.6.2 CD4 cell count classification and WHO clinical staging 
The CD4 cell count of the participants were categorised into three groups using the Centers for 
Disease Control and Prevention classification as follows: ≥500 cells/µl, 200-499 cells/µl, and 
<200 cells/µl (CDC, 1993).  
The WHO clinical staging system for adults (WHO, 2005) sorts patients into one of four 
hierarchical clinical stages ranging from stage 1 (asymptomatic) to stage 4 (AIDS). At the point 
of entry into the HIV care programme of the clinic, each patient was assigned to a particular 
stage if they demonstrated at least one clinical condition in that stage’s criteria. Because patients 
remain at a higher WHO stage after they recover from the clinical condition which placed them 
in that stage, they are not re-staged in the course of management (Malamba, Morgan, Clayton, 
Mayanja, Okongo & Whitworth, 1999). The details of the WHO clinical staging system is shown 
in Appendix 7. 
3.6.3 Drug adherence  
Adherence to HAART was assessed using both tablet counting and self-reporting methods. In the 
tablet counting method, pharmacy medication records for patients were matched by the 
pharmacist against the not-yet-used medicines brought to the pharmacy by the patients as a 
routine for refill of prescriptions and the number of doses that ought to have been taken that were 
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missed were recorded (Era & Arute, 2008). Patient’s self-reporting method was carried out as 
previously described by Weiser et al. (2003). In this method, patients were interviewed about 
their adherence over the previous day, previous week and previous month successively in an 
attempt to minimize recall bias. In both methods, adherence was defined as taking 95% of 
prescribed doses over the previous month which corresponded to missing no more than one dose 
in a 10-day period [in a 2 times a day dosing regimen], one dose per week [in a 3 times a day 
regimen] or one dose per month [in a once daily regimen] (Era & Arute, 2008). Patients were 
therefore said to have HAART non-adherence if they missed more than 5% of their doses. Where 
there was discrepancy between the rates obtained by the two methods, adherence rate obtained in 
the counting method was used.  Cotrimoxazole adherence was determined in the same manner as 
stated above for HAART adherence.  
3.7 Data collection  
A structured questionnaire (Appendix 6) was used as the data collection tool. The questionnaires 
were administered to the patients by 3 clinical staff at the adult ARV clinic supervised by the 
researcher. The information contained in the questionnaire was based on parameters judged to be 
relevant to the study from the available literature. The information was separated into 3 sections. 
Section A was for the socio-demographic data. Section B contained the relevant medical history 
and physical examination findings while Section C captured the laboratory investigation results 
such as CD4 cell count, sputum AFB, chest x-ray, stool microscopy, cerebrospinal fluid (CSF) 
analysis, blood, sputum and urine cultures as well as tissue histology where appropriate. For 
patients who required further laboratory investigation for the diagnosis of HIV-related OD, 
samples were collected on the spot (as already explained to them before they consented) and the 
laboratory results were entered as soon as they were available. Some clinically-relevant 
instruments that were used in the study included stadiometer for height measurement, weighing 
scale, mercury clinical thermometer and a digital camera. The digital camera was used to obtain 
pictures of externally-visible diagnoses such as oral candidiasis, dermatitis, and Kaposi’s 
sarcoma after obtaining informed consent. Patients’ were assured that their facial identity will be 
concealed when the pictures will be displayed. Data collection involving contact with the 
patients spanned a period of 11 weeks.  
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3.8 Sample collection, storage and laboratory analysis 
Depending on the clinical presentation of the patient, relevant specimens were collected such as 
sputum, oropharyngeal swab, high vaginal swab, stool, blood, urine, CSF. Microbiology samples 
for culture collected early in the day (8:00-12:00) were inoculated and subsequently incubated 
within official working hours (before 16:00) while those collected later in the day (14:00-16.00) 
were preserved in –80 ⁰C freezer for analysis the following morning. All samples were 
appropriately labeled and handled according to standard biosafety regulations. With the 
exception of histology, sample storage and analysis was carried out at the FHI-facilitated 
laboratory at the FMC Owerri. This is a modern laboratory with dedicated standby generator 
which ensures constant electricity supply for adequate preservation of samples in a –80 ⁰C 
freezer.  
For TB, three sputa specimen were collected – spot sample at first contact with the patient, early 
morning sample the following day and another spot sample at the time of submission of the early 
morning sample. All three samples were used to make separate smears and stained by Ziehl-
Neelsen method for AFB. Sputum AFB samples were routinely collected and analysed in the 
morning hours as part of the TB laboratory protocol so did not require storage. Direct saline and 
iodine mounts were prepared for stool samples and examined under the microscope for ova, 
larvae, trophozoites or cysts of intestinal parasites. For coccidian parasites such as 
cryptosporidium, stool specimens were examined by modified Ziehl-Neelsen technique. For 
candidiasis, oropharyngeal or vaginal swab specimens were cultured on to Sabouraud’s dextrose 
agar and the fungal colonies were subsequently identified by the germ tube test. Cerebrospinal 
fluid preliminary microscopy and chemistry samples were routinely analysed on an emergency 
basis so did not require storage. In the CSF samples, cryptococcus was examined for by Indian 
ink wet mount. Bacteriological identification of organisms in the sputum for bacterial pneumonia 
employed both Gram staining techniques and culture in appropriate media. Aerobic and 
anaerobic blood cultures were carried out using appropriate media.   
Venous blood samples for CD4 cell quantification were collected in the mornings and analysed 
within 2-3 hours using flow cytometry as obtainable in the laboratory protocol due to instability 
of CD4 cells in vitro. The haematology samples were analysed on the day of collection using 
haematology autoanalyser while blood chemistry samples were collected in appropriate sample 
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bottles and stored in a –80 ⁰C freezer for analysis within 24-48 hours using a blood chemistry 
autoanalyser. Biopsy samples collected following clinical diagnosis of Kaposi’s sarcoma or TB 
lymphadenitis were preserved in formalin and moved to the histopathology laboratory of the 
hospital for histology.  
 
3.9 Validity, reliability and generalizability  
In order to ensure validity, a systematic sampling technique with a random starting point was 
adopted to minimize bias and to give every participant an equal chance of being selected. In 
addition, to eliminate confounding from HIV-related ODs ante-dating the commencement of 
HAART, only patients who had received HAART for a minimum of 12 weeks were selected. 
The 12 week period was to ensure that such patients had received HAART long enough to have 
achieved virological suppression and immunogical recovery. As much as possible OD diagnosis 
was based on standard definitions. Logistic regression analysis was used to control for potential 
confounders for OD risk factors. 
To ensure reliability, a pilot testing of the questionnaire was carried out and pertinent minor 
modifications made. Also, before a clinical diagnosis of an OD was accepted, at least 2 
physicians involved in HIV care and management were required to agree on the diagnosis and 
this was subsequently confirmed by laboratory investigations where relevant and possible. Due 
to difficulties in TB diagnosis in PLHIV, relevant TB screening and diagnostic algorithms were 
employed and where smear positivity or histologic diagnosis was not possible, additional 
supportive laboratory evidence and clinical response to treatment were employed to strengthen 
TB diagnosis. With the exception of histology, all the laboratory investigations were carried out 
in the same laboratory (FHI-sponsored laboratory, FMC, Owerri) using the same protocol for 
specific investigations with standard quality assurance guidelines. At least two trained laboratory 
scientists were required to agree on each laboratory diagnosis before it was accepted. Data 
analysis was carried out independently by the statistician and the researcher and the findings 
compared for conformity.     
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To improve generalizability, the study participants were selected from a general population of 
HIV-infected patients on HAART at the clinic. In addition, a random sampling technique was 
used to ensure that each individual had an equal chance of being selected.  
3.10 Ethical considerations 
Ethical clearance for the study was obtained from the Higher Degree Committee of the 
University of the Western Cape (UWC), South Africa (Appendix 1) and the Ethics Committee of 
Federal Medical Centre, Owerri, Nigeria (Appendix 2). An informed consent form (Appendix 
3/4) was signed or thumb-printed by each patient before recruitment. Prior to this, the study and 
what it entailed was fully explained to the participants (Appendix 5). All information obtained 
from the patients as well as their laboratory investigation results were handled with 
confidentiality. Individuals diagnosed to have any OD were referred for appropriate treatment. 
The patients were not asked to pay any money for any part of the study. They were made to 
understand that participation in the study was voluntary and that they were at liberty to withdraw 
from the study at any stage without prejudice to their future management. 
3.11 Data analysis 
3.11.1. Data handling and cleaning 
During data collection, questionnaires were constantly checked for errors. Data entry and analysis 
were carried out using the Epi Info version 3.5.1 statistical software (CDC, Atlanta, Georgia, 2008) 
and Open Epi Version 2.2.1. Two separate Epi Info views were created, one by the researcher and 
another by a statistician. Data entries from the questionnaires were then carried out using designated 
codes independently in the two Epi Info views. At the end of data entry, all the variables in the two 
views were listed and the data sets were compared for discrepancies and incomplete entries. 
Observed discrepancies were investigated by recourse to the specific questionnaire(s) affected and 
the corrections were effected. For discrepancies or errors which could not be corrected by reference 
to the questionnaire(s), the hospital folders or laboratory result data base were contacted for 
verification. Any issues which remained unresolved were subsequently classified as incomplete 
data. Out of the 354 questionnaires administered, 15 were classified as having incomplete data so 
only 339 were included in the final data analysis.  
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3.11.2 Descriptive and analytical statistics 
For descriptive statistics, frequency tables of categorical variables were made both for socio-
demographic variables (such as gender, occupation, socio-economic class, ethnicity, and 
residence) and clinical parameters (such as OD presence, HAART adherence, cotrimoxazole 
prophylaxis, and WHO clinical stage). Prevalence of HIV-related ODs was described as a simple 
proportion in percentage first as an aggregate variable and then for the individual ODs. Measures 
of central tendency (mean and median) and dispersion (standard deviation, SD; interquartile 
range, IQR) were used to describe numeric variables. Mean (SD) was used for normally 
distributed variables such as age, BMI, haemoglobin while median (IQR) was used to describe 
non-normally distributed parameters such as CD4 cell count, duration of HIV diagnosis, and 
duration of HAART.   
In terms of univariate analytical statistics, the Chi-square test was used to determine significance of 
association between OD and various socio-demographic and clinical variables. When the expected 
cell values were less than 5, Fisher’s exact test was used. The Student “t”-test was used to compare 
group means or median values. For multivariate analysis, backward stepwise logistic regression was 
used to determine the independent socio-demographic and clinical risk factors for the occurrence of 
ODs (as an aggregate variable) using parameters that had a p-value of <0.25 on univariate analysis. 
However, parameters which a priori were known risk factors for OD which had p-value >0.25 were 
also included in the logistic model. All reported p-values <0.05 were considered statistically 
significant.   
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CHAPTER FOUR 
       RESULTS 
4.1: Socio-demographic characteristics of the study participants 
Out of the 354 patients that consented to the study and had questionnaires administered on them, 
339 had complete responses and laboratory results. The socio-demographic characteristics of the 
study participants are shown in Table 4.1. The participants were between 18 and 68 years with a 
mean age of 41.1 ± 10.0 years. The highest number of participants was between 31-40 years 
(36.0%). Female subjects were in the majority (65.8%). As shown in Fig. 4.1, men were 
significantly older  with a mean age of 46.8 ± 9.2 years compared to 38.1 ± 9.2 years in women, 
p<0.0001. 
Most of the participants were either married (59.3%) or widowed (20.6%). The majority (73.1%) 
of them had at least secondary level of education. The predominant occupations were trading 
(41%), civil service (19.8%) and farming (8.3%). Thirty four (10.0%) were unemployed. They 
were largely of Igbo ethnicity (93.2%); the remaining participants belonged to other ethnic 
groups including Efik/Ibibio- 9 (2.7%), Hausa/Fulani- 7 (2.1%), Tiv-5 (1.5%), and Yoruba- 2 
(0.6%). Urban dwellers had a slight majority (56.3%). One hundred and eighty six (54.9%) 
patients had a household income of less than 20,000 Naira per month (<133 US dollars per 
month). The predominant household size was 5-8 persons per household reported in 158 (47.6%) 
of the participants. The number of rooms in the apartment where the participants resided ranged 
from 1 to 4 with a fairly equal distribution.  Ninety eight (28.9%) reported having more than two 
people inclusive of themselves in a room. Half of the respondents (50.4%) were in the lower 
socio-economic class while only 27 (8.0%) were in the upper class.  
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Table 4.1: Socio-demographic characteristics of the study participants 
Characteristic N=339 
n (%) 
Gender 
Female 
Male 
 
223 (65.8) 
116 (34.2) 
Age (years) 
≤ 30 
31-40 
41-50 
51-60 
>60 
 
51 (15.0) 
122 (36.0) 
106 (31.3) 
41 (12.1) 
19 (5.6) 
Marital status 
Married 
Single 
Separated/divorced 
Widowed 
 
201 (59.3) 
46 (13.6) 
22 (6.5) 
70 (20.6) 
Occupation 
Trader 
Civil servant 
Farmer 
Technician 
Student 
Others 
Unemployed 
 
139 (41.0) 
67 (19.8) 
28 (8.3) 
13 (3.8) 
20 (5.9) 
38 (11.2) 
34 (10.0) 
Educational status 
None 
Primary 
Secondary 
Tertiary 
 
7 (2.1) 
84 (24.8) 
158 (46.6) 
90 (26.5) 
Household income (Naira, =N=) 
<20,000 
20-50,000 
 
186 (54.9) 
73 (21.5) 
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51-100,000 
>100,000 
50 (14.7) 
30 (8.8) 
Household size/No of dependents 
≤4 
5-8 
>8 
 
114 (34.3) 
158 (47.6) 
60 (18.1) 
Rooms in apartment 
1 
2 
3 
4 
 
80 (23.6) 
99 (29.2) 
69 (20.4) 
91 (26.8) 
People per room 
≤2 
>2 
 
241 (71.1) 
98 (28.9) 
Socio-economic class 
Upper (class I) 
Middle (class II & III) 
Lower (class IV & V) 
 
27 (8.0) 
141 (41.6) 
171 (50.4) 
Ethnicity 
Igbo 
Others 
 
316 (93.2) 
23 (6.8) 
Residence 
Urban 
Rural 
 
191 (56.3) 
148 (43.7) 
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Fig. 4.1: Age distribution of the participants by gender 
 
4.2 Clinical characteristics of the study participants 
The clinical characteristics of the study participants are shown in Table 4.2. The duration of HIV 
diagnosis among the study participants ranged from 6 months to 10 years with a median (IQR) of 
3.4 (2.0-6.0) years. There was no difference between men and women in terms of duration of 
HIV diagnosis; 3.5 (2.0-6.0) and 3.3 (2.0-5.6) years respectively (p=0.77).  The duration of 
HAART ranged from 4 months to 118 months (9.8 years) with a median of 35 (20-50) months. 
There was also no difference between men and women in the median duration of HAART, 36 
(22-54) months and 34 (20-48) months respectively (p=0.11). The majority (77.6%) were 
adherent on HAART. Two hundred and ninety seven (87.6%) participants were receiving 
cotrimoxazole prophylaxis with an adherence rate of 75.1%.  
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At baseline (i.e. at entry point pre-HAART), most of the participants belonged to either WHO 
clinical stage 1 (41%) or stage 2 (31.3%).  The median baseline CD4 cell count of the patients 
was 200 (110-263) cells/µl and only 12 (3.5%) had baseline CD4 cell count ≥500 cells/µl. Their 
mean baseline haemoglobin was 11.2 ± 2.0 g/dl and 76 (22.4%) had anaemia at baseline. The 
median current CD4 cell count of the patients was 357 (211-496) cells/µl and 84 (24.8%) had 
CD4 cell count ≥500 cells/µl. Their mean current haemoglobin was 11.6 ± 1.8 g/dl and only 36 
(10.6%) had anaemia. The mean current BMI of the participants was 24.5 ± 5.5 kg/m
2
 and 51 
(15.0%) were underweight. Seventy three (21.2%) had a past history of TB treatment, 52 
(15.3%) had hypertension, and 11 (3.2%) had diabetes mellitus. Positive history of on-going 
alcohol consumption was recorded in 72 (21.2%) participants while 24 (7.1%) were current 
smokers. 
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Table 4.2:  Clinical characteristics of the study participants 
Characteristics N=339 
Duration of HIV diagnosis (years), median (IQR)  3.4 (2.0-6.0) 
Duration of HAART (months), median (IQR) 35.0 (20.0-50.0) 
HAART adherence,
†
 n (%) 263 (77.6) 
Cotrimoxazole prophylaxis, n (%) 297 (87.6) 
Cotrimoxazole adherence (N=297), n (%)  223 (75.1) 
Baseline WHO clinical stage 
1 
2 
3 
4 
 
139 (41.0) 
106 (31.3) 
76 (22.4) 
18 (5.3) 
Baseline CD4 cell count (cells/µl) 
<200 
200-499 
≥ 500 
Current CD4 cell count (cells/µl) 
<200 
200-499 
≥500 
Baseline haemoglobin (g/dl), mean ± SD 
 
168 (49.6) 
159 (46.9) 
12 (3.5) 
 
75 (22.1) 
180 (53.1) 
84 (24.8) 
11.2 ± 2.0 
Current haemoglobin (g/dl), mean ± SD 11.6 ± 1.8 
BMI (current) [Kg/m
2
], mean ± SD  24.5 ± 5.4 
Past history of TB treatment 73 (23.7) 
Hypertension 52 (15.3) 
Diabetes mellitus 11 (3.2) 
Alcohol consumption 72 (21.2) 
Cigarette smoking  24 (7.1) 
BMI= body mass index; HAART= highly active antiretroviral therapy; HIV=human immunodeficiency 
virus; IQR=interquartile range; TB=tuberculosis; SD=standard deviation; WHO=world health 
organisation 
†Adherence refers to the proportion of patients with drug adherence level of >95%. The reported 
adherence was based on both self-reported and tablet counting methods.  
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4.3 Prevalence of opportunistic diseases 
Out of 339 participants, 76 had diagnosed opportunistic disease(s) giving an overall prevalence 
of 22.4% (95% C.I 18.2-27.3%) (Fig. 4.2). The overall prevalence of OD was similar in men, 24 
(20.7%) and women, 52 (23.3%). The highest overall prevalence of OD was recorded in those 
between 31 and 40 years (35.5%), closely followed by the 41-50 years (30.3%), and ≤30 years 
(27.6%) age groups. 
 
 
Fig. 4.2: Overall prevalence of opportunistic diseases in the study participants 
OD= opportunistic disease 
 
The prevalence of individual ODs is shown in Fig. 4.3. The most prevalent ODs were 
candidiasis, 29 (8.6%); TB, 26 (7.7%); and dermatitis 19 (5.6%). Other recorded ODs were 
chronic diarrhoea seen in 5 (1.5%), sepsis 5 (1.5%), cryptococcal meningitis 2 (0.6%), bacterial 
pneumonia 2 (0.6%), herpes zoster 2 (0.6%), genital herpes 2 (0.6%), genital warts 2 (0.6%), and 
Kaposi’s sarcoma 1 (0.3%). In relative terms, candidiasis, TB and dermatitis, constituted 38.2%, 
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34.2%, and 25% of the ODs respectively. The pictures of some of the patients with externally 
visible ODs are shown in Appendix 8.  
 
 
Fig. 4.3: Prevalence of individual opportunistic diseases in the study participants 
 
Of the 76 patients in whom ODs were recorded, 52 (68.4%) had single ODs, 20 (26.3) had dual 
ODs while 1 person (1.3%) had triple ODs. The prevalence of dual/triple ODs among the study 
participants is shown in Fig. 4.4. The most prevalent dual OD condition was TB/candidiasis seen 
in 7 (2.1%) patients, followed by TB/dermatitis seen in 3 (0.88%) patients. TB/herpes zoster, 
candidiasis/chronic diarrhea, candidiasis/genital warts and candidiasis/dermatitis were each seen 
in 2 (0.59%) patients. The other dual/triple ODs were seen in only 1 (0.29%) patient and 
included candidiasis/dermatitis/sepsis, cryptococcal meningitis/genital herpes and 
candidiasis/genital herpes.  
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Fig. 4.4: Prevalence of dual/triple opportunistic diseases in the study participants  
TB= tuberculosis; CM= cryptococcal meningitis 
 
 
Among the three common ODs diagnosed, candidiasis was more prevalent in women (10.8%) 
than in men (4.3%). After excluding vaginal candidiasis, the prevalence of oral candidiasis was 
still slightly higher in women (6.3%) than in men (4.3%). Although the number of individuals 
with TB was equal in terms of gender, the prevalence of TB was higher in men, 13 (11.2%) 
compared to women, 13 (5.8%). Dermatitis was commoner in women with a prevalence of 7.2% 
compared to 2.6% in men. The prevalence of the three common ODs (candidiasis, TB and 
chronic dermatitis) by age groups is shown in Fig. 4.5. Candidiasis (23.5%) and dermatitis 
(11.8%) were most prevalent in participants ≤30 years while the prevalence of TB was highest in 
patients aged 41-50 years (11.3%).  
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Fig. 4.5: Prevalence of common opportunistic diseases by age groups  
 
 
4.4 Clinical details of the opportunistic diseases 
The clinical details of the common ODs seen in the study participants are shown in Table 4.3. 
All the cases of candidiasis had Candida albicans as the isolate. In terms of site of candida 
lesion, oral candidiasis was predominant and either occurred alone, 12 (41.4%), or co-existed 
with vaginal candidiasis in women, 7 (24.1%).  
Among the patients with TB, 11 (42.3%) were pulmonary while 9 (34.6%) were disseminated 
TB. All the cases of disseminated TB had clinical/radiological evidence of pulmonary 
involvement. The cases of extra-pulmonary TB involved the pleura (11.5%), lymph node (7.7%), 
and abdomen (3.8%). Of the 20 patients with evidence of pulmonary involvement, 9 (45%) had 
smear positive disease. The commonest symptoms in those with TB were weight loss (96.2%), 
fever (92.3%), and chronic cough (88.5%). Dermatitis was predominantly of fungal cause 
(63.2%).  
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Among the 5 patients with chronic diarrhoea, the isolates were Cryptosporidium, 2 (40%); 
Giardia intestinalis 2 (40%) while the remaining patient had no organism isolated. The bacterial 
isolates in the blood culture of the 5 patients with sepsis were Salmonella typhi, 2 (40%); 
Klebsiella spp, 2 (40%); and Staphylococcus aureus, 1 (20%). The 2 participants with bacterial 
pneumonia had Streptococcus pneumoniae isolated.  
Among the three common ODs, the least median duration of HAART was seen in those with 
candidiasis (12 months) followed by TB (16 months). The lowest current median CD4 cell count 
was recorded in those with TB (165 cells/µl), followed by candidiasis (183 cells/µl). Dermatitis 
occurred at a relatively higher median CD4 cell count of 246 cells/µl.  
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Table 4.3: Clinical details of the common opportunistic diseases seen in the study participants 
OD characteristics  
CANDIDIASIS (N=29) 
Site, n (%) 
Oral 
Vaginal 
Oral + Vaginal 
Current CD4 cell count (cells/µl), median (IQR) 
Duration of HAART (months), median (IQR) 
 
 
12 (41.4) 
10 (34.5) 
7 (24.1) 
183 (142-427) 
12 (6-24) 
 
TUBERCULOSIS (N=26) 
Site, n (%) 
Pulmonary 
Pleura 
Lymph node 
Abdomen 
Disseminated 
Symptoms, n (%) 
Chronic cough  
Fever 
Weight loss 
Night sweat 
Sputum smear positivity
†
, n (%) 
Yes 
No 
Current CD4 cell count (cells/µl), median (IQR) 
Duration of HAART (months), median (IQR) 
 
 
11 (42.3) 
3 (11.5) 
2 (7.7) 
1 (3.8) 
9 (34.6) 
 
23 (88.5) 
24 (92.3) 
25 (96.2) 
16 (61.5) 
 
9 (45.0) 
11 (55.0) 
165 (85-216) 
16 (6-36) 
 
DERMATITIS (N=19) 
Type, n (%) 
Fungal 
Scabies 
Non-infective 
Current CD4 cell count (cells/µl) , median (IQR) 
Duration of HAART (months), median (IQR) 
 
 
12 (63.2) 
2 (10.5) 
5 (26.3) 
246 (144-392) 
41 (20-84) 
†Sputum smear positivity refers to the 20 patients with evidence of pulmonary involvement 
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4.5:  Risk factors for opportunistic diseases in the study participants 
As shown in Table 4.4, the socio-demographic variables that had a significant association with 
the risk of OD on univariate analysis included the following: age ≤40 years (p=0.02), lower 
socio-economic class (p=0.03), household income <20,000 Naira (p=0.0002), and having >2 
people per room (p=0.002). The risk of OD did not significantly differ according to gender, place 
of residence or marital status.   
The univariate analysis of clinical risk factors for ODs is shown in Table 4.5. Occurrence of OD 
was significantly associated with HIV diagnosis <3 years (p<0.0001), duration of HAART <36 
months (p<0.003), and HAART non-adherence (p<0.0001). The following baseline parameters 
were associated with increased risk of OD: WHO clinical stage 3-4 (p<0.0001), CD4 cell count < 
200 cells/µl (p<0.0001), and haemoglobin <10 g/dl (p<0.0001). In addition, the risk of OD was 
significantly higher in participants with the following current parameters: CD4 cell count <200 
cells/µl (p<0.0001), haemoglobin <10 g/dl (p<0.0001), and BMI <25 Kg/m
2
 (0.047). There was 
no significant relationship between occurrence of OD and cotrimoxazole prophylaxis, diabetes, 
hypertension, alcohol consumption or smoking.  
In order to determine the independent risk factors for OD, age, household income, residence, 
number of people per room, socio-economic status, duration of HIV diagnosis, HAART 
duration, HAART adherence, baseline WHO clinical stage, CD4 cell count (baseline and 
current), haemoglobin (baseline and current), and BMI were included in multivariate analysis 
(logistic regression) as they all had p<0.25 on univariate analysis. Although gender had a p-value 
of 0.58 on univariate analysis, it was also included in the logistic model as it was one of the 
variables considered a priori to be associated with OD risk. Finally, the independent risk factors 
for OD were household income <20,000 Naira, duration of HIV diagnosis <3 years, baseline 
WHO clinical stage 3-4, HAART non-adherence, baseline haemoglobin <10 g/dl, and current 
CD4 cell count <200 cells/µl (Table 4.6). The odds of having OD remained two times higher in 
participants ≤40 years but did not attain statistical significance (Adjusted odds ratio,  AOR=1.89, 
95% CI 0.92-3.89, p=0.08).  
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Table 4.4: Socio-demographic risk factors for opportunistic diseases (univariate analysis) 
Variable OD present 
N= 76 
n (%) 
No OD  
N = 278 
n (%) 
Odds ratio 
(95% CI) 
p-value 
Age (years) 
>40  
≤40 
 
28 (36.8) 
48 (63.2) 
 
138 (52.5) 
125 (47.5) 
 
1.0 
1.89 (1.12-3.20) 
 
 
0.02 
Gender 
Female 
Male 
 
52 (68.4) 
24 (31.6) 
 
171 (65.0) 
92 (35.0) 
 
1.0 
1.17 (0.68-2.01) 
 
 
0.58 
Socio-economic class 
Upper 
Middle 
Lower 
 
2 (2.6) 
28 (36.8) 
46 (60.5) 
 
25 (9.5) 
113 (43.0) 
125 (47.5) 
 
1.0 
3.10 (0.69-13.86) 
4.60 (1.05-20.19) 
 
 
0.12 
0.03 
Residence 
Urban 
Rural 
 
38 (50.0) 
38 (50.0) 
 
153 (58.2) 
110 (41.8) 
 
1.0 
1.39 (0.83-2.32) 
 
 
0.21 
Marital status 
Single/separated/divorced/widowed 
Married 
 
35 (46.1) 
41 (53.9) 
 
103 (39.2) 
160 (60.8) 
 
1.0 
1.33 (0.79-2.22) 
 
 
0.28 
Household income (Naira, =N=) 
≥20,000 
<20,000  
 
20 (26.3) 
56 (73.7) 
 
133 (50.6) 
130 (49.4) 
 
1.0 
2.86 
 
 
0.0002 
People per room 
≤2 
>2 
 
43 (56.6) 
33 (43.4) 
 
198 (75.3) 
65 (24.7) 
 
1.0 
2.33 (1.36-3.98) 
 
 
0.002 
OD= opportunistic disease 
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Table 4.5: Clinical risk factors for opportunistic diseases (univariate analysis) 
Variable OD present 
N= 76 
n (%) 
No OD  
N = 278 
n (%) 
Odds ratio 
(95% CI) 
p-value 
HIV duration (years) 
≥3 
<3 
 
35 (46.1) 
41 (53.9) 
 
187 (71.1) 
76 (28.9) 
 
1.0 
2.88 (1.65-5.04) 
 
 
<0.0001 
Duration of HAART (months) 
≥36 
<36 
 
26 (34.2) 
50 (65.8) 
 
140 (53.2) 
123 (46.8) 
 
1.0 
2.19 (1.29-3.89) 
 
 
0.003 
HAART adherence 
Yes 
No 
 
35 (46.1) 
41 (53.9) 
 
228 (86.7) 
35 (13.3) 
 
1.0 
7.63 (4.30-13.55) 
 
 
<0.0001 
Cotrimoxazole prophylaxis 
Yes  
No 
 
66 (86.8) 
10 (13.2) 
 
231 (87.8) 
32 (12.2) 
 
1.0 
0.91 (0.43-2.04) 
 
 
0.81 
Baseline WHO clinical stage 
1-2 
3-4 
 
26 (34.2) 
50 (65.8) 
 
44 (16.7) 
219 (83.3) 
 
1.0 
9.48 (5.37-17.05) 
 
 
<0.0001 
Baseline CD4 cell count (cells/µl) 
≥200 
<200 
 
20 (26.3) 
56 (73.7) 
 
151 (57.3) 
112 (42.6) 
 
1.0 
3.76 (2.14-6.65) 
 
 
<0.0001 
Current CD4 cell count (cells/µl) 
≥200 
<200 
 
38 (50.0) 
38 (50.0) 
 
226 (85.9) 
37 (14.1) 
 
1.0 
6.11 (3.46-10.78) 
 
 
<0.0001 
Baseline haemoglobin (g/dl) 
≥10 
<10 
 
41 (53.9) 
35 (46.1) 
 
222 (84.4) 
41 (15.6) 
 
1.0 
4.62 (2.64-8.10) 
 
<0.0001 
 
Current haemoglobin (g/dl) 
≥10 
<10 
 
58 (76.3) 
18 (6.8) 
 
245 (76.3) 
18 (23.7) 
 
1.0 
4.22 (2.07-8.62) 
 
 
<0.0001 
BMI (current) [Kg/m
2
] 
≥25 
<25 
 
23 (30.3) 
53 (69.7) 
 
113 (43.0) 
150 (57.0) 
 
1.0 
1.74 (1.01-3.00) 
 
 
0.047 
Diabetes 
Yes 
No 
 
1 (1.3) 
75 (98.7) 
 
10 (3.8) 
253 (96.2) 
 
1.0 
0.34 (0.02-2.06) 
 
 
0.28 
Hypertension 
Yes 
No 
 
9 (11.8) 
67 (88.2) 
 
43 (16.3) 
220 (83.7) 
 
1 
0.69 (0.30-1.45) 
 
 
0.34 
Alcohol consumption 
No 
Yes  
 
61 (80.3) 
15 (19.7) 
 
206 (78.3) 
57 (21.7) 
 
1.0 
0.89 (0.47-1.68) 
 
 
0.72 
Smoking 
No 
Yes 
 
69 (90.8) 
6 (9.2) 
 
246 (93.5) 
57 (21.7) 
 
1.0 
1.18 (0.45-3.11)` 
 
 
0.73 
BMI= body mass index; HAART= highly active antiretroviral therapy; OD= opportunistic 
disease; WHO= world health organisation 
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Table 4.6: Risk factors for opportunistic diseases (multivariate analysis) 
 Adjusted Odds ratio  95% CI P-value 
Age ≤40 years 1.89 0.92-3.89 0.08 
Household income <20,000 Naira 2.38 1.11-5.08 0.03 
Duration of HIV diagnosis <3 years 2.12 1.05-4.24 0.004 
Baseline WHO clinical stage 3-4 8.14 4.03-16.44 <0.0001 
HAART
 
non-adherence 5.42 2.63-11.18 <0.0001 
Baseline haemoglobin <10g/dl 2.87 1.33-6.15 0.007 
Current CD4 cell count <200 cells/µl 2.98 1.42-6.23 0.004 
Corrected for gender, residence, number of people per room, socio-economic class, HAART duration, 
BMI, baseline CD4 cell count, and current haemoglobin, 
HAART= highly active antiretroviral therapy; WHO= world health organisation 
 
4.6 Specific associations of the common opportunistic diseases  
The specific relationship between selected socio-demographic variables and each of the three 
common opportunistic diseases was further evaluated as shown in Tables 4.7-4.9. Rural 
residence was significantly associated with increased risk of dermatitis (p=0.02). Although 
candidiasis, TB, and dermatitis were all commoner in people of lower socio-economic class 
compared to middle and upper classes, none showed a statistically significant association (Table 
4.8). The association of male gender with TB (p=0.08), and that of dermatitis with female gender 
(p=0.08) both fell short of attaining statistical significance.  
Past history of TB treatment was a risk factor for current diagnosis of TB. Tuberculosis was 
diagnosed in 15 (20.5%) participants with a past history of TB compared to a TB prevalence of 
4.7% in those without past history of TB, OR= 5.23, 95% CI 2.27-12.34, p<0.0001. The 
association between current diagnosis of TB and past history of TB remained significant after 
controlling for other relevant socio-demographic and clinical parameters in a multivariate 
analysis (Table 4.10), AOR= 5.30, 95% CI 1.39-20.21`, p=0.02. 
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Table 4.7: Relationship between gender and common opportunistic diseases  
Specific OD Male (N=116) Female (N=223) p-value 
Tuberculosis 
Yes 
No 
 
13 (11.2) 
103 (88.8) 
 
13 (5.8) 
210 (94.2) 
 
0.08 
 
Candidiasis
† 
(oral) 
Yes 
No 
 
5 (4.3) 
111 (95.7) 
 
14 (6.3) 
209 (93.7) 
 
0.45 
Dermatitis 
Yes 
No 
 
3 (2.6) 
113 (97.4) 
 
16 (7.2) 
207 (92.8) 
 
0.08 
† 
Patients with only vaginal candidiasis were excluded from this analysis since vaginal candidiasis is a 
disease of women; OD= opportunistic disease 
 
 
Table 4.8: Relationship between socio-economic class and common opportunistic diseases 
Specific OD        Socio-economic class  p-value 
  Upper (N=27) Middle (N=141) Lower (171)  
Candidiasis 
Yes 
No 
 
1 (3.7) 
26 (96.3) 
 
9 (6.4) 
132 (93.6) 
 
19 (11.1) 
152 (98.9) 
 
0.21 
 
Tuberculosis 
Yes 
No 
 
1  (3.7) 
26 (96.3) 
 
7 (5.0) 
134 (95.0) 
 
18 (10.5) 
153 (89.5) 
 
0.13 
 
Dermatitis 
Yes 
No 
 
0 (0.0) 
27 (100.0) 
 
8 (5.7) 
133 (94.3) 
 
11 (6.4) 
160 (93.6) 
 
0.40 
 
OD= opportunistic disease 
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Table 4.9: Relationship between place of residence and common opportunistic diseases 
Specific OD Rural (N=148) Urban (N=191) p-value 
Tuberculosis 
Yes 
No 
 
13 (8.8) 
135 (91.2) 
 
13 (6.8) 
178 (93.2) 
 
0.50 
 
Candidiasis 
Yes 
No 
 
13 (8.8) 
135 (91.2) 
 
16 (8.4) 
175 (91.6) 
 
0.89 
Dermatitis 
Yes 
No 
 
13 (8.8) 
135 (91.2) 
 
6 (3.1) 
185 (96.9) 
 
0.02 
OD= opportunistic disease 
 
Table 4.10: Risk factors for tuberculosis (multivariate analysis) 
Risk factors Adjusted Odds ratio  95% CI p-value 
Past history of TB treatment 5.30 1.39-20.21 0.015 
Duration of HIV diagnosis <3 years 0.1 0.01-0.71 0.022 
HAART duration <36 months 8.15 1.15-57.66 0.036 
HAART
 
non-adherence 168.22 19.89-1422.62 <0.0001 
Baseline CD4 cell count <200 cells/µl 31.35 2.79-351.57 0.005 
Current haemoglobin <10g/dl 14.22 2.40-84.33 0.003 
Corrected for age, gender, number of people per room, household income, socio-economic class, 
smoking, HAART duration, BMI, current CD4 cell count, baseline haemoglobin, and baseline WHO 
clinical stage 
HAART= highly active antiretroviral therapy; TB= tuberculosis  
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CHAPTER FIVE 
  DISCUSSION  
5.1 Discussion 
This study determined the prevalence of opportunistic diseases in patients receiving HAART in a 
resource-limited setting in Nigeria and further highlighted the socio-demographic and clinical 
risk factors associated with their occurrence. In this study, the highest number of participants was 
between 31 and 40 years, an observation that has been corroborated by several studies both in 
developed and developing countries (Palella et al., 1998; Lawn, Badri & Wood, 2005; 
Srirangaraj & Venkatesha, 2011). This represents the bulk of the sexually active population 
which incidentally is the most economically productive age group. The tendency for HIV 
infection and its attendant complications to have their greatest impact on this group will 
definitely have a negative effect on the socio-economic achievements of SSA which is home to 
over 70% of the PLHIV globally. The majority of the participants were females. Some studies in 
West Africa have also shown a predominantly female HIV-infected population (Seyler, Toure, 
Messou, Bonard, Gabillard & Anglaret, 2005; Losina et al., 2007). This contrasts sharply with 
studies in Western countries, Asia and some parts of SSA which documented a male 
predominance (Forrest et al., 1998; Yazdanpanah et al., 2001; Sun et al., 2006; Komati et al., 
2010). While the finding of this study is supportive of the female predominance among PLHIV 
in Nigeria (FMOH, 2010), it may also be reflective of a better health-seeking behaviour among 
women in a public HIV care and treatment centre.  More than half of the participants belonged to 
the lower social class; and 55% had a monthly household income below 20,000 Naira which is 
about the national minimum wage in Nigeria. Although HIV is not necessarily a disease of the 
poor, Singh et al. (2003) and Lawn et al. (2005) also made a similar observation in India and 
South Africa respectively. Over 40% of the participants were rural dwellers despite the fact that 
the study site was in an urban area. This may be suggestive of limited availability of HIV care 
and treatment centres in rural areas in the country.  
The baseline clinical characteristics show that 50% of the patients had advanced immunological 
disease at first presentation despite the observation that 72% had clinically mild disease at this 
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point based on WHO clinical staging. Several authors have shown that late immunological 
disease presentation has continued to be a problem among PLHIV in developing countries 
despite health education programmes and scaling up of ART (Sun et al., 2006; Losina et al., 
2007; Daniyam et al., 2011). The median duration of HAART (3 years) paralleled the median 
duration of HIV diagnosis (3.4 years) which suggests a good time response between HIV 
diagnosis and HAART commencement. The HAART adherence rate of 78% is in agreement 
with the adherence rate of 77% reported across SSA in a meta-analysis (Mills et al., 2006). The 
23.7% self-reported rate of past TB treatment in this study is in accordance with 14-37% 
reported elsewhere in developing countries (Lawn et al., 2005; Ghate et al., 2009; Komati et al., 
2010).  
The overall prevalence of ODs found in this study was 22.4%. This is in agreement with the rate 
of 20% documented by Corey et al. (2007) in a 5-year observational cohort study of 564 patients 
receiving HAART in Peru, South America. It is also comparable with the report of De Beaudrap 
et al., (2010) where 30% of their cohorts receiving HAART in Senegal, West Africa, developed 
ODs. Variable OD rates in patients on HAART have been reported in other settings, 8% in 
Thailand (Manosuthi et al., 2007); 8.3% in India (Srirangaraj & Venkatesha, 2011); 47.6% both 
in Taiwan (Sun et al., 2006) and South Africa (Mzileni, Longo-Mbenza & Chepha, 2008). The 
high rate of 47.6% found in Taiwan is double the rate in this study and sharply contrasts with the 
much lower rates of 8% in the other HAART-experienced Asian populations (Manosuthi et al., 
2007; Srirangaraj & Venkatesha, 2011). Although the pre-HAART burden of ODs was not stated 
in most of the reports, the high rate of 47.6% in Taiwan may be attributable to the high OD 
prevalence of 77.7% in their patients before commencement of HAART. Mzileni et al. (2008) in 
South Africa studied a large cohort of 2,605 between 2004 and 2006 and found OD prevalence 
double that of this study although the focus of the study regarding ODs was on the 204 patients 
that died in that study. It is important to state that beyond differences in sample size and study 
design, as well as possible differences in pre-HAART OD burden between the cohorts of Mzileni 
et al. (2008) and the patients in this study, the 6-8 years time difference between their study and 
this study is a strong factor. Over this time, access to ART has significantly been scaled up both 
in South Africa and Nigeria so the findings of this study may be more reflective of the current 
trends of OD prevalence in sub-Saharan African patients enjoying a relatively better access to 
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HAART. The median duration of HAART at the time of determination of OD prevalence in 
Peru, Asia and South Africa ranged from 6 months to 3 years and this could have also 
contributed to the differences in OD prevalence across these developing countries.  
Although the absolute prevalence rates for individual ODs were low in this study, candidiasis 
(8.6%), TB (7.7%), dermatitis (5.6%), chronic diarrhoea (1.5%) and sepsis (1.5%) were the most 
prevalent conditions. In relative terms, of the 76 patients diagnosed with ODs, candidiasis, TB, 
and dermatitis were suffered by 38.2%, 34.2%, and 25%, respectively. The most frequent ODs 
that occurred during HAART in the patients in this study are similar to those seen in patients 
receiving HAART in other low-income settings with TB, candidiasis, systemic bacterial 
infections  being among the leading ODs (Sun et al., 2006; Mzileni, Longo-Mbenza & Chepha, 
2008; Seyler, Messou, Gabillard, Inwoley, Alioum & Anglaret, 2007; De Beaudrap et al., 2010).  
The spectrum of ODs in HAART patients in this study is virtually similar to what was reported 
in HAART-naïve patients in Nigeria (Salami et al., 2006; Daniyam et al., 2011). Lack of change 
in the spectrum of ODs post-HAART has been observed by several authors (Forest et al., 1998; 
Ledergerber et al.; 1999; Sun et al., 2006; De Beaudrap et al., 2010). It is worth mentioning that 
unlike most of these studies, TB was not the commonest OD among our patients despite the 
well-known high burden of TB in Nigeria. It is possible that TB was under-diagnosed in our 
patients considering the difficulty associated with TB diagnosis in PLHIV especially in the 
absence of sputum mycobacterial cultures.  This does not in any way undermine the fairly strict 
criteria that were employed in arriving at TB diagnosis in this study. TB diagnosis remains a 
challenge in PLHIV due to absence of classical features, high rate of smear negative disease, and 
relatively high burden of extra-pulmonary disease all of which are attributable to 
immunosuppression. This is not the case for candidiasis which is a lot easier to diagnose whether 
on clinical or laboratory grounds.  
Compared to OD prevalence of 56.7 - 68.6% in HAART-naïve HIV-infected patients in Nigeria 
(Daniyam, Iroezindu, Shehu, Essien, Sati & Agaba, 2011; Saidu, Bunza, Abubakar, Adamu, 
Ladan & Fana, 2009; Salami, Olatunji & Oluboyo, 2006),  the OD prevalence of 22.4% in this 
study suggests a decline in OD prevalence by 60-67% post-HAART in the Nigerian context. 
However, since there is no evidence that the pre-HAART burden of ODs among the patients in 
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this study carried out in Southern Nigeria is the same as the rates of 56.7-68.6% in HAART-
naïve patients reported in the three studies in Northern Nigeria (Daniyam, Iroezindu, Shehu, 
Essien, Sati & Agaba, 2011; Saidu, Bunza, Abubakar, Adamu, Ladan & Fana, 2009; Salami, 
Olatunji & Oluboyo, 2006), this assumption cannot be stretched too far. In Senegal, De Beaudrap 
et al. (2010) reported an impressive decline in OD rate of 79% in their cohorts at the fourth year 
on HAART compared to their baseline OD burden. Unfortunately, this was not sustained beyond 
this time as the OD incidence began to rise by 5% per month after the fourth year. In Taiwan, the 
rate of OD decline was only 39% after 12 months of HAART. Despite the longer duration of 
HAART use in western countries, the rate of OD decline in the era of HAART has remained 
consistent and more impressive with over 80% decline in the rates of ODs (Palella et al., 1998; 
Lerdergerber et al., 1999; Kaplan et al., 2000). While it is not in doubt that that the relatively 
lower burden of ODs in the pre-HAART era, and widespread access to ART in high-income 
settings have reasonably contributed to this subtle difference, efforts to identify possible 
contributions of clinical and socio-demographic characteristics of PLHIV in developing 
countries is worthwhile.  
A number of independent clinical risk factors for the occurrence of ODs were identified in this 
study including HIV duration less than 3 years, advanced WHO clinical stage at baseline, 
anaemia at baseline, current CD4 cell count less than 200 cells/µl, and HAART non-adherence. 
Similarly, the clinical risk factors for ODs in HAART–experienced patients in other studies 
include low level of current CD4 cell count, advanced baseline WHO clinical stage, and baseline 
anaemia (Lerdergerber et al., 1999; Kaplan et al., 2000; Lawn et al., 2005; De Beaudrap et al., 
2010; Komati et al., 2010; Srirangaraj & Venkatesha, 2011). Additional clinical parameters 
which have also been identified as determinants of OD in patients receiving HAART include low 
baseline CD4 cell count, shorter duration of HAART, high viral load at baseline or in the course 
of treatment, and low BMI. Apart from viral load which was not quantified in this study due to 
economic constraints, the other additional factors were all significantly associated with the 
presence of ODs on univariate analysis in this study but their effect was not significant on 
multivariate analysis. It is possible that this study did not have enough power to investigate the 
association between some of these additional clinical parameters and risk of OD. The increased 
risk of OD associated with shorter duration of HIV infection has not been extensively 
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investigated especially in SSA. Considering that the scaling up of ART is relatively recent in 
SSA, it is possible that those who have had HIV infection for longer periods have possibly 
suffered more mortality following life-threatening ODs which could create the impression that 
the burden of OD is higher in those whose duration of HIV infection is shorter. Another possible 
argument is that if those who have had HIV infection for a longer duration have also received 
HAART much longer, then they are likely to have a more robust immune recovery and less 
likely to suffer HIV-related ODs. In this regard, a number of studies have found shorter duration 
of HAART to be associated with higher risk of OD (Lerdergerber et al., 1999; Hung & Chang, 
2004; Losina et al., 2007).  
The independent association between HAART non-adherence and occurrence of ODs 
documented in this study should be taken seriously. This observation was made despite the 
relatively good adherence with 78% of our patients taking 95% or more of their doses. While 
there is a tendency to focus on patient-related factors when HAART non-adherence is discussed 
in HIV treatment centres, we cannot afford to lose sight of the contribution of system failure in 
ART programmes. In 2004, the national ART programme of Nigeria suffered a major setback 
when it was hit by shortage of drugs (Monjok, Smesny, Okokon, Mgbere, & Essien, 2010). As a 
result, many patients were off drugs or staggered their dosages for up to 3 months which led to a 
structurally-induced adherence problem. Although the programme subsequently resumed when 
drug supplies were recommenced, till date, we probably do not know the exact contribution of 
that tragedy to antiretroviral treatment failure in Nigeria. In appreciation of the challenge non-
adherence poses to the current benefits of HAART, Yazdanpanah et al. (2001) declared: 
“moreover, due to issues of adherence, resistance, failure and cross-resistance, there will likely 
be many patients who remain at major risk for the development of opportunistic infections [in 
the era of HAART].”  
Another important finding was that past history of TB treatment was an independent risk factor 
for TB, an observation that was also reported by Syler et al. (2005). While Komati et al. (2010) 
identified past history of TB to predict TB occurrence during HAART on univariate analysis, 
this association was not upheld after controlling for other factors. On the other hand, Lawn et al. 
(2005) found no association between past history of TB and TB occurrence during HAART. As 
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suggested by Seyler et al. (2005): “reporting a higher incidence of TB in patients with a history 
of TB inevitably leads to question if the TB episodes were more frequent relapses from persistent 
bacilli rather than re-infection with new bacilli occurring since the previous episode.” 
In developed nations, emphasis on the risk factors for ODs has largely been on clinical 
parameters which have led to baseline CD4 cell count and post-treatment CD4 cell count being 
acknowledged as the strongest predictors of HIV-related OD (Ledergerber et al., 1999; Kaplan, 
Hanson, Jones & Dworkin, 2001). SSA with its long list of socio-economic determinants of 
health cannot afford to endlessly tow this line. In this study, poor household income was found to 
be an independent predictor of ODs. Although lower socio-economic class was a strong predictor 
of OD on univariate analysis, this effect was lost after controlling for other factors. It may also 
be noteworthy that overcrowding (having more than 2 people per room) which is an index of 
poverty was associated with increased OD risk on univariate analysis. According to Lawn et al. 
(2005) socio-economic class was not found to have a significant impact on TB risk in South 
African cohorts. Nevertheless, overcrowding and poor hygiene have been suggested as 
contributory factors to high burden of OD in developing countries (Srirangaraj & Venkatesha, 
2011). Bearing in mind the finding of this study, household income on its own may be more 
intimately associated with health challenges than other factors such as educational status and 
occupation which in addition to income contribute to the socio-economic designation of the 
individual. If the relationship between poverty and OD risk in low-income countries is supported 
by more studies, PLHIV in Nigeria will be in great danger of ODs considering that 55% of the 
participants of this study had a household income below the national minimum wage.  
Furthermore, younger patients (≤40 years) tended to be at an increased risk of ODs. While Lawn 
et al. (2005) demonstrated increased risk of TB in younger patients (<33 years), Ghate et al. 
(2009) in a predominantly HAART-naïve population in India reported that older age was a 
strong determinant of ODs. Pallela et al. (1998) found no association between age and OD risk in 
a cohort of US patients. In line with the observations of Pallela et al. (1998) and Lawn et al. 
(2005), we did not find gender to be a strong risk factor for ODs. Contrarily, male gender was 
found to be strongly associated with the occurrence of ODs in other reports (Manosuthi et al., 
2007; Komati et al., 2010). Large prospective cohort studies are needed to investigate the 
 
 
 
 
 51 
 
association between socio-demographic variables and HIV-related ODs in the era of HAART in 
developing countries.  
5.2 Limitations 
This study had some limitations which include the following: 
1. HIV viral load of the patients was not carried out. This is due to the fact that HIV treatment 
programmes in Nigeria are running on very tight budgets for over two years such that HIV 
viral load which is very expensive (running cost of $66 per sample) is no longer done except 
for initial evaluation prior to commencement of HAART in a few selected centres.  
2. The diagnosis of herpes zoster and genital warts were entirely based on clinical grounds. In 
addition, some relatively less common HIV-related ODs in SSA for which diagnostic 
facilities are not readily available such PCP, MAC and CMV disease were not diagnosed. 
Although a high index of suspicion was maintained for PCP, none of the participants met the 
clinical criteria for its presumptive diagnosis.  
3. It was not possible to do sputum mycobacterial culture for the diagnosis of pulmonary TB 
which would have significantly increased the sensitivity of pulmonary TB diagnosis. This is 
due to the high cost of the test and its non-availability in South-east Nigeria. However, the 
TB screening and diagnostic algorithm in HIV-infected patients was combined with sputum 
AFB test, radiological investigations and treatment response (in some cases) to improve the 
sensitivity of TB diagnosis. 
4. The impact of antiretroviral drug resistance was not determined as the sophisticated facilities 
for antiretroviral resistance testing are not available in most parts of Nigeria. In the few 
places this could be done, the cost is usually prohibitive.  
5. The relatively small number of patients with TB in this study may call for cautious 
interpretation of our findings regarding the risk factors associated with TB on multivariate 
analysis. For example, duration of HIV diagnosis less than 3 years surprisingly comes across 
as protective of TB while the odds ratio for HAART non-adherence as a TB risk factor is 
extremely high.  
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6. Cotrimoxazole use had no effect on the occurrence of ODs on univariate analysis and 
subsequently was not included in the logistic regression model. Cotrimoxazole use is known 
to improve morbidity and mortality in PLHIV (Walker et al., 2010). While this observation 
may be considered as a potential limitation of this study, it is possible that some of the 
patients whose pharmacy records captured that they were on cotrimoxazole prophylaxis were 
actually not consuming the drug.  
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CHAPTER 6 
      CONCLUSION AND RECOMMENDATIONS 
6.1 Conclusion 
In this mini-thesis, the prevalence of HIV-related opportunistic diseases (ODs) was determined 
among patients receiving HAART in a resource-limited setting in Nigeria. The clinical and 
socio-demographic risk factors of the HAART patients were also described and their associations 
with the occurrence of ODs were investigated. The overall prevalence of ODs was found to be 
22.4% which is within the range of 8-48% reported in HAART-experienced patients in low-
income countries. Among the 76 patients diagnosed to have ODs, candidiasis (38.2%), TB 
(34.2%), dermatitis (25%), chronic diarrhoea (6.6%) and sepsis (6.6%) were the leading 
conditions. While this may be suggestive of some reasonable decline in OD prevalence 
compared to studies in HAART-naïve groups in Nigeria, the spectrum of ODs has largely 
remained the same.  
Fifty one percent (51%) of the participants were ≤40 years, and the majority of them were 
females (65.8%). Over 40% of the participants were rural dwellers, 50.4% belonged to the lower 
socio-economic class, and 55% had a monthly household income below 20,000 Naira.  The 
baseline clinical characteristics showed that 50% of the patients had advanced 
immunosuppression at first presentation despite the observation that 72% had clinically mild 
disease at this point based on WHO clinical staging. The median duration of HAART (3 years) 
paralleled the median duration of HIV diagnosis (3.4 years) and HAART adherence rate was 
high with 78% of patients being adherent. Past history of TB treatment was reported by 23.7%. 
The independent risk factors for the occurrence of ODs were poor household income, HIV 
duration less than 3 years, advanced WHO clinical stage at baseline, anaemia at baseline, low 
level of current CD4 cell count, and HAART non-adherence. In addition, younger age tended to 
be associated with increased risk of OD. Past history of TB was found to be a strong predictor of 
TB. These findings suggest that ODs remain a challenge in patients receiving HAART in 
Nigeria. Beyond the well recognised clinical predictors of HIV-related ODs, poverty may 
emerge a strong determinant of HIV-related ODs in developing countries.  
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6.2 Recommendations 
Based on the findings of this study, the following recommendations are put forward: 
1. A high index of suspicion should be maintained for opportunistic diseases in PLHIV 
despite the use of HAART considering that one-fifth of patients receiving HAART in this 
study were found to have at least one opportunistic disease.  
2. Health education on HIV screening and early presentation should be intensified to 
encourage early diagnosis, and prompt access to HIV care and treatment. This is because 
individuals who presented late for the first time (i.e at an advanced WHO clinical stage) 
were found to be eight times more likely to come down with an opportunistic disease 
while on HAART compared to those who presented when their clinical disease was mild.  
3. Anaemia should be properly investigated for during baseline evaluation in PLHIV and 
when present should be appropriately corrected to achieve normal haemoglobin 
concentrations. This is because patients who were anaemic pre-HAART were found to 
have a three times increased risk of suffering opportunistic diseases after commencement 
of HAART independent of immunological recovery.  
4. Individuals who continue to have low CD4 cell count while on HAART should be 
aggressively evaluated for opportunistic diseases and practical efforts to optimize their 
immunological recovery should be made which may involve evaluation for drug 
resistance followed by appropriate drug switch.  
5. As recommended by WHO/TB-HIV Working Group (WHO, 2011), active case finding 
for TB and wide use of isoniazid preventive therapy in eligible HIV-infected patients 
should be widely promoted.  
6. Prophylaxis for fungal infections especially candidiasis should be widely implemented in 
the routine management PLHIV in endemic regions such as SSA after exclusion of active 
disease, irrespective of HAART use. This can be standardized as the widely practiced 
cotrimoxazole prophylaxis whose benefits have been impressive. 
7. Low-income groups should become a target for a more aggressive evaluation for HIV-
related opportunistic diseases. While HIV/AIDS is not necessarily a disease of the poor, 
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this study found that individuals earning below the Nigerian national minimum wage 
were twice more likely to suffer opportunistic diseases. 
8. HAART adherence counselling should be intensified in patients receiving HAART. 
Management of adherence problems may involve identifying the peculiar individual, 
social, and structural factors affecting HAART adherence with a view to addressing 
them. Measures that may be instituted could include use of treatment partners, use of 
alarm reminders, reducing pill burdens, and drug switch following non-tolerable side 
effects. The need for improved commitments of indigenous governments in SSA towards 
sustained availability and accessibility of ART cannot be overemphasized.  
9. Earlier initiation of HAART before progression to advanced immunosuppression should 
be encouraged in order to decrease the likelihood of opportunistic diseases. 
10. Use and adherence to Cotrimoxazole prophylaxis should continue to be encouraged until 
patients on HAART achieve sustained immunological recovery as recommended by 
WHO guidelines (WHO, 2006). 
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APPENDIX 3 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
 Tel: 021- 959 2809, Fax: 021- 959 2872 
 
PARTICIPANT INFORMATION SHEET 
I am Iroezindu Michael, a student studying for the Masters in Public Health degree at the 
University of the Western Cape, South Africa. I am gathering information in the form of a 
research from people living with HIV/AIDS on treatment who are 15 years and above. I am 
trying to find out the types of unusual infections and cancers (known as opportunistic diseases) 
that occur in this group of people and the risk factors that make them occur. The study will be 
used for obtaining a Masters degree. In addition, the findings may lead to recommendations that 
may improve patient management. I would like to ask you some questions, conduct physical and 
laboratory examination which will take about 15-30 minutes of your time. Samples of blood, 
skin and other body fluids may be collected from you and the process of obtaining some samples 
such as blood may cause transient discomfort. You may choose not to participate in this study 
and you also have the freedom to withdraw from the study if you so desire and this will not 
affect you or your treatment in any way. Your identity, contact details and any information you 
give me will not be disclosed to anyone. Below is the Igbo language version of this participant 
information. 
Researcher’s name: IROEZINDU MICHAEL. 
Address: DEPARTMENT OF MEDICINE, FEDERAL MEDICAL CENTRE, OWERRI, 
NIGERIA.            
Telephone: +2347031376345, +2348028614747.  
E-mail: mikezindu@yahoo.com  
 
Should you have any questions regarding this study or wish to report any problem you have 
experienced related to the study, please contact the study supervisors (see below)
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APPENDIX 4 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
     Tel: 021- 959 2809, Fax: 021- 959 2872 
            
  IHE ONYEOBULA KWESIRI IMA 
Aha m bu Iroezindu Michael, nwa akwukwo na-acho inweta akara nke Masters na Public Health 
na University of the Western Cape, South Africa.  Ana m eme ihe omumu research gbasara ndi 
nwere Oria Obere n’aja ocha ndi na-anu ogwu ndi di afo iri na ise ma o bu karia. Ihe m na-
achoputa bu maka oria ndi digasi anaa a na-akpo oppotunistic diaseases. Nchoputa a ga-enyere 
m aka i nmeta akara Masters. Ozokwa, o ga-enyekwa aka ime ka ogwugwo ndi oria obere na-aja 
ocha di nma karia. A ga m aju gi ufodu ajuju, lee gi ahu ma mee kwa gi ule obara na ule ndi ozo 
di iche iche nke ga-ewe oge nwere ike rue nkeji hour. Imiri obara nwere ike ifu gi obere ufu nwa 
mgbe nta. I nwere ike isi na ihe omumua a masighi gi ma obukwa wepu onwe gi oge obula 
ichoro ma o nweghi ihe obula nke a ga-ebutere gi. Onweghi onye obula a ga-agwa ihe gbasara  
gi. 
 
Aha onye na-eme nchoputa: IROEZINDU MICHAEL. 
Addressi: DEPARTMENT OF MEDICINE, FEDERAL MEDICAL CENTRE, OWERRI, 
NIGERIA.            
Ekwe nti: +2347031376345, +2348028614747. 
E-mail: mikezindu@yahoo.com.  
 
O buru na i choro iju ajuju ozo ma obu n’inwere nsogbu nihi nchoputa a, i nwere ike ime 
ka ndi isi ihe nchoputa a mara. E dere aha ha n’okpuru ebe a.   
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Supervisor’s Name:  Prof. Harry Hausler 
   University of the Western Cape 
   Private Bag X17, Belville 7535 
   South Africa. 
   Cell:  +2782 779 0045 
   Email: hhausler@tbhivcare.org  
 
Co-supervisor’s Name: Dr. Brian Van Wyk 
   University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: +2721959-2173 
Cell: +2782 911 0904 
Fax: +27 21 959 2872 
Email: bvanwyk@uwc.ac.za  
 
 
If you are willing to participate in the study, please read and sign the consent form below. 
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             APPENDIX 5 
RECORD OF AN INFORMED CONSENT TO CONDUCT AN INTERVIEW 
Date: …………………………. 
Interviewer’s name: IROEZINDU MICHAEL 
Tel: +2347031376345 or + 2348028614747 
UWC Student no: 3002900 
E-mail: mikezindu@yahoo.com  
Institution: University of the Western Cape 
Interviewees’ pseudonym:      
Interview site: Heart to Heart Centre, Federal Medical Centre, Owerri.  
Thank you for agreeing to allow me interview you. What follows is an explanation of the 
purpose and process of this interview. You are advised to give your consent to participate in this 
interview which will involve asking you some questions, conducting a physical examination on 
you and collecting your blood sample (and samples from other body parts if required) for 
laboratory investigations. This data will be used for my research to acquire a Masters degree at 
the School of Public Health, University of the Western Cape, South Africa. 
 
1. Information about the interviewer: I am Iroezindu Michael, a student at the School of 
Public Health, University of the Western Cape. As part of my Masters in Public Health, I am 
required to carry out a research and write a report. I will be focusing on HIV-related 
opportunistic diseases in the era of HAART in a resource-limited setting. I am accountable to my 
supervisors; Hausler Harry and Van Wyk Brian. 
2. Purpose of interview: The purpose of my interview is to fulfill the part of my Masters in 
Public Health. The content will be questions that will centre on finding out about opportunistic 
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diseases in HIV-infected patients on HAART. The research will culminate into writing a report 
for the Masters in Public Health degree of University of the Western Cape. 
3. The interview process: Will involve getting a clearance, an interviewee, consent signing to 
participate, questionnaire administration, physical examination and laboratory investigation. 
4. Anonymity of contributors: At all times, I will keep the source of the information 
confidential and refer to you or your words by a pseudonym or invented name which I would 
like you to choose. I shall keep any or the record of your participation locked away at all times, 
and destroy them after the data has been collected. 
5. Things that may affect your willingness to participate: The interview may touch on issues 
which may affect your willingness to participate. If there is anything that you would prefer not to 
respond to, please feel free to say so. I will not be offended and there will be no negative 
consequences if you would prefer not to answer a question. I would appreciate your guidance 
should I ask anything which you see as intrusive. 
6. Agreement  
6.1. Interviewee’s agreement 
The respondent will be asked to give his/her consent in writing or thumb printing 
6.2. Interviewee’s agreement 
I shall keep the contents of the above research interview confidential in the sense that the 
pseudonym noted above will be used in all documents which refer to the interview. The contents 
will be used for the purposes referred to above, but may be used for published or unpublished 
research at a later stage without further consent. Any change from this agreement will be 
renegotiated with you. If you are willing to participate in the study please sign below. 
Participant’s signature/thumbprint  Date     Venue ______________ 
Witness signature/thumbprint   Date      Venue ______________ 
 
Investigators signature   Date     Venue ______________ 
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 Appendix 6:  Questionnaire 
PREVALENCE OF HIV-RELATED OPPORTUNISTIC DISEASES AMONGST HAART 
PATIENTS AT THE FEDERAL MEDICAL CENTRE IN OWERRI, NIGERIA 
NOTE: Kindly respond to the following questions by filling the boxes using the relevant codes 
provided beside each box where applicable. 
SECTION 1: SOCIO-DEMOGRAPHIC DATA 
1. Patient’s File Number:     
2. What is your Gender?   Male=1, Female =2   
3.  What is your age (in years)?      
4. What is your marital status?  Single=1, Married=2, Separated/Divorced=3,  
        Widowed=4   
5. What is your ethnicity? Igbo=1, Hausa/Fulani=2, Yoruba=3,    
         Southern minorities=4, Northern minorities=5, 
6a. What is your occupation?   Civil Servant=1, Trader=2,   Farmer=3, Student=4   
              Housewife =5, Technician=6, Others=7, Unemployed=8 
6b. What is the occupation of your spouse?  (Indicate the occupation of your father instead if you are 
under the care your parents) 
 Civil Servant=1, Trader=2,   Farmer=3, Student=4  Housewife =5, Technician=6, 
 Others=7, Unemployed=8 
7a. What is your highest educational level?  None=1, Informal=2, Primary=3,  
             Secondary =4, Tertiary =5  
7b.What is the highest educational level of your spouse? (Indicate that of your mother instead if 
you are under the care your parents) 
None=1, Informal=2, Primary=3, Secondary =4, Tertiary =5  
8. What is the nature of your place of residence:   Rural=1          Urban =2 
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9. How many rooms do you have in your apartment?  1 room =1, 2 rooms =2,  
             3 rooms =3, ≥ 4 rooms = 4  
10. How many people share your room with you?  None=1, 1 person =2, 2 persons =3, ≥ 3 
persons =4  
11. What is your household monthly income? < N20, 000 =1; N20, 000-50,000 = 2,  
                 N51, 000-100, 000 = 3; > N100, 000 = 4 
12. How many people are dependent on your household income?   
None =1, ≤ 4 people =2, 5-8 people =3,  >8 People = 4   
13. Socio-economic class: To be completed by the researcher as Class 1, 2, 3, 4 or 5 using 
information obtained from numbers 6-12 above. 
SECTION 2:  CLINICAL INFORMATION 
History 
14. Kindly indicate if you have any of these medical complaints listed below including the    
 duration of the complaint. 
i) Fever Yes=1, No=2, duration………(specify days/weeks/months) 
ii) Cough    Yes=1, No=2, duration……………………(specify days/weeks/months) 
iii) Weight loss    Yes=1, No=2, duration……………(specify days/weeks/months) 
iv) Night sweats    Yes=1, No=2, duration……………(specify days/weeks/months) 
v) Diarrhoea    Yes=1, No=2, duration…………………(specify days/weeks/months) 
vi) Headache   Yes=1, No=2, duration…………………(specify days/weeks/months) 
vii) Neck pain  Yes=1, No=2, duration……………………(specify days/weeks/months) 
viii) Skin rashes/growth Yes=1, No=2, duration…………(specify days/weeks/months) 
ix) White patches in the mouth   Yes=1, No=2, duration…... (specify days/weeks/months) 
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x) Mouth ulcers Yes=1, No=2, duration………………(specify days/weeks/months) 
xi) Ulcers in the genitals  Yes=1, No=2, duration………(specify days/weeks/months) 
xii) Vaginal or penile discharge Yes=1, No=2, duration……..(specify days/weeks/months) 
xiii) Others (Specify)………………………, duration……..(specify days/weeks/months) 
15. Duration of HIV diagnosis (in years)    (specify number of months if < 1 year) 
16. Duration of ART (in months)         
17. ART adherence in the past 6 months  Yes=1       No=2 
      (Answer Yes/No with respect to your duration of ART if less than 6 months) 
18. Are you taking Co-trimoxazole prophylaxis?  Yes=1       No=2 
19. Co-trimoxazole adherence in the past 6 months?    Yes=1 No=2 (Answer Yes/No with 
respect to the duration if less than 6 months) 
20. Have you had TB treatment in the past?  Yes=1       No=2 
20. Do you smoke cigarette? Yes=1       No=2 
22. Do you take alcohol? Yes=1       No=2 
PHYSICAL FINDINGS AND DIAGNOSIS 
23. Anthropometry:  
a) Height……….. (m), b) Weight……… (Kg), c) Body Mass Index (BMI)…………. (Kg/m2) 
24. General examination……………………………………………………………………….  
25. Skin abnormalities…………………………………………………………………………. 
26. CNS findings……………………………………………………………………………… 
27. Respiratory findings ……………………………………………………………………… 
28. Abdominal findings……………………………………………………………………….  
29. CVS findings……………………………………………………………………………… 
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30. Opportunistic disease (OD) clinical diagnosis made 
a) …………………………………………………………………………………………….  
b) ……………………… …………………………………………………………………… 
c) ……………………………………………………………………………………………. 
31. WHO clinical stage at baseline:   1         2       3        4 
 
SECTION 3: LABORATORY INVESTIGATIONS 
32. CD4 cell count (cells/µl): baseline………………., Current…………………. 
33. Sputum Smear for AFB (x3)   
      Sample 1   Positive=1       Negative=2 
      Sample 2   Positive=1       Negative=2 
      Sample 3   Positive=1       Negative=2    
      Final interpretation of Sputum AFB   Positive=1       Negative=2 
34. Complete blood count + ESR 
      Haemoglobin (g/dl)……………………………………………………… 
      WBC ( x 10
6
/l):  
       Total…………………… 
      Differential: Neutro….., Lympho…….,Mono………, Eosino………, Baso……… 
      Platelet count (x 10
6
/l)…………………………………………………. 
      ESR (mm/hour)…………………………………………………… 
35. Culture results (Specify specimen)……………………………………… 
36. CSF findings…………………………………………………… 
37. Histology report (Specify specimen)……………………………. 
38. Chest X-ray findings…………………………………………….. 
39. Others (specify)…………………………………………………. 
 
 
 
 
 78 
 
APPENDIX 7: WHO CLINICAL STAGING (WHO, 2005) 
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APPENDIX 8  
PICTURES OF SOME EXTERNALLY VISIBLE OPPORTUNISTIC DISEASES IN THE 
STUDY PARTICIPANTS 
 
 
Fig. i: Kaposi’s sarcoma affecting the right lower limb in a 46 year old man on HAART  
 
 
 
Fig. ii: Oral candidiasis in a 38 year old woman on HAART  
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Fig. iii: Dermatitis (non-infective) in a 29 year old woman on HAART 
 
 
 
Fig iv: Dermatitis (Fungal) in a 49 year old man on HAART 
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Fig. v: Genital warts co-existing with vaginal candidiasis in a 28 year old woman on 
HAART 
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   APPENDIX 9 
                           SAMPLE SIZE TABLE (The Research Advisors, 2006) 
 
  
 
 
 
 
